Aclaris Therapeutics, Inc.   
Protocol Number: A -101-WART -202 
Page 1 of 53 
Amendment 2 
Date:    05 December  2017 CLINICAL STUDY PROTOCOL  
Protocol Number: A-101-WART -202 
05 December  2017  
Amendment 2 
Version 3 
A RANDOMIZED, DOUBLE -BLIND, VEHICLE -CONTROLLED, PARALLEL GROUP 
STUDY OF A -101 TOPICAL SOLUTION APPLIED ONCE A WEEK IN SUBJECTS 
WITH COMMON WARTS  
Sponsor  
Acla ris Therapeutics, Inc.  
101 Lindenwood Drive  
Suite 400  
Malvern, PA 19355  
Telephone: (484) 324-7933  
Facsimile: (484) 320-2344  
Study Contact  
Judy Schnyder  
Aclaris Therapeutics, Inc.  
101 Lindenwood Drive  
Suite 400  
Malvern, PA 19355  
Telephone:  484 -329-2144  
Email:  jschnyder@aclaristx.com  
Medical Monitor  
Evyan Cord -Cruz , MD  
Symbio   
21 Perry Street  
Port Jefferson, NY 11777  
Main Number Telephone:  631-403-5126  
Office Number:  516 -338-0647  
Mobile Number:  516 -982-0677  
Serious Adverse Event Facsimile:  484 -324-2359  
Email:  ecruz@symbioresearch.com  
This document is a privileged and confidential communication of A claris Therapeutics, Inc.  Acceptance of this 
document constitutes an agreement by the recipient that no unpublished information contained herein will be used, 
published or disclosed without prior written approval from A claris Therapeutics, Inc .
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 3 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
INVESTIGATOR SIGN ATURE PAGE  
Protocol Number :  A-101-WART -202 
 
Protocol Title :  A Randomized, Double -Blind, Vehicle -Controlled, Parallel -Group Study of A -101 
Topical Solution Applied Once a Week in Subjects with Common Warts  
Protocol Version  Version 3.0: 05 December 2017  
 
I have reviewed the above -titled protocol and agree that it contains all the information necessary to 
conduct the study as required.  I will conduct the trial in accordance with the principles of ICH Good 
Clinical Practice and the Declaration of Helsinki.  
I will maintain as confidential all written and verbal information provided to me by the Sponsor, 
including but not limited to, the protocol, case report forms, investigator’s brochure, material supplied at 
investigator meetings, minutes of teleconferences , etc.  Such material will only be provided as necessary 
to site personnel involved in the conduct of the trial, involved IRBs or local regulatory authorities.  
I will obtain written informed consent /assent  from each prospective trial subject  or each prospe ctive trial 
subject ’s legal representative prior to conducting any protocol -specified procedures.  The Informed 
Consent Document used will have the approval of the IRB appropriate for my institution.  
 
I will maintain adequate source documents and record al l observations, treatments and procedures 
pertinent to trial patients in their medical records.  I will accurately complete the case report forms 
supplied by the Sponsor in a timely manner.  I will ensure that my facilities and records will be available 
for inspection by representatives of the Sponsor, the IRB, and/or local regulatory authorities.  I will 
ensure that I and my staff are available to meet with Sponsor representatives during regularly scheduled 
monitoring visits.  
I will notify the Sponsor with in 24 hours of any serious adverse events.  Following this notification, a 
written report describing the serious adverse event will be provided to the Sponsor as soon as possible, 
but no later than five days following the initial notification.  
 
    
Investi gator Name (print)  
             
Investigator’s Signature       Date  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 4 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                         Table of Contents  
1. SYNOPSIS  ................................ ................................ ................................ ................................ ....................  7 
LIST OF ABBREVIATIONS AND DE FINITIONS OF TERMS  ................................ .............................  11 
2. INTRODUCTION  ................................ ................................ ................................ ................................ ...... 13 
2.1. Summary  ................................ ................................ ................................ ................................ ...................  13 
2.2. Study Rationale  ................................ ................................ ................................ ................................ ........  15 
3. OBJECTIVES  ................................ ................................ ................................ ................................ .............  16 
3.1. Study Objectives  ................................ ................................ ................................ ................................ ...... 16 
3.1.1 . Primary Objective  ................................ ................................ ................................ ................................  16 
3.1.2.  Secondary Objective  ................................ ................................ ................................ ............................  16 
4. STUDY DESIGN  ................................ ................................ ................................ ................................ ........  16 
4.1. Number of Subjects and Study Centers  ................................ ................................ .............................  17 
4.2. Duration of Study  ................................ ................................ ................................ ................................ .... 17 
5. STUDY ENTRY CRITERIA  ................................ ................................ ................................ ..................  17 
5.1. Inclusion Criteria  ................................ ................................ ................................ ................................ .... 17 
5.2. Exclusion Criteria  ................................ ................................ ................................ ................................ ... 18 
5.3. Removal of Patients from St udy Therapy  ................................ ................................ .........................  19 
5.4. Withdrawal Procedures  ................................ ................................ ................................ .........................  19 
5.5. Subject Replacement  ................................ ................................ ................................ ..............................  19 
5.6. Subject Identifier (SI)  ................................ ................................ ................................ .............................  20 
6. STUDY PROCEDURES  ................................ ................................ ................................ ...........................  20 
7. STUDY TREATMENT ................................ ................................ ................................ .............................  24 
7.1. Investigational Study Medication  ................................ ................................ ................................ ........  24 
7.2. Subject Randomization  ................................ ................................ ................................ ..........................  24 
7.3. Study medication packaging, st orage and dispensing  ................................ ................................ .... 25 
7.4. Drug Accountability  ................................ ................................ ................................ ................................  25 
7.5. Weighing of Study Medication Applicators  ................................ ................................ ......................  25 
7.6. Study Medication Treatment  ................................ ................................ ................................ ................  26 
7.6.1.  Preparing the Study Medication for Application  ................................ ................................ .........  26 
7.6.2.  Applying Study Medication to Target and Non -Target Warts on the Trunk and 
Extremities  ................................ ................................ ................................ ................................ .............  28 
7.7. Dose modification  ................................ ................................ ................................ ................................ .... 29 
7.8. Previous and Concomitant Therapies  ................................ ................................ ................................  30 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 5 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   7.8.1.  Previous therapies  ................................ ................................ ................................ ................................  30 
7.8.2.  Concomitant therapies  ................................ ................................ ................................ ........................  30 
7.8.3.  Prohibited therapies  ................................ ................................ ................................ .............................  30 
7.9. Breaking the Blind  ................................ ................................ ................................ ................................ .. 31 
8. ASSESSMENTS OF CLINICAL EFFICACY  ................................ ................................ ....................  32 
8.1. Target and Non -Target Wart Identification  ................................ ................................ .....................  32 
8.2. Standardized photography  ................................ ................................ ................................ ....................  33 
8.3. Physician’s Wart Assessment  (PWA)  ................................ ................................ ................................ . 34 
8.4. Subject Instructions  ................................ ................................ ................................ ................................  34 
8.5. Other Study Supplies  ................................ ................................ ................................ ..............................  35 
9. ASSESSMENT OF SAFETY  ................................ ................................ ................................ ..................  35 
9.1. Local Skin Reactions (LSR)  ................................ ................................ ................................ ..................  36 
9.2. Vital signs  ................................ ................................ ................................ ................................ ..................  37 
9.3. Clinical laboratory sampling  ................................ ................................ ................................ ................  37 
9.4. Urine pregnancy tests  ................................ ................................ ................................ .............................  38 
9.5. Other Evaluations  ................................ ................................ ................................ ................................ ... 38 
9.5.1.  Demographics and medical history  ................................ ................................ ................................ .. 38 
9.5.2.  Standardized photography  ................................ ................................ ................................ .................  39 
10. ADVERSE EVENTS  ................................ ................................ ................................ ................................  40 
10.1.  Definitions  ................................ ................................ ................................ ................................ .................  40 
10.1.1.  Adverse events (AE)  ................................ ................................ ................................ .............................  40 
10.1.2.  Serious adverse event (SAE)  ................................ ................................ ................................ ..............  41 
10.1.3.  Adverse event reporting period  ................................ ................................ ................................ .........  41 
10.1.4.  Severity  ................................ ................................ ................................ ................................ ....................  42 
10.1.5.  Relationship to study medication  ................................ ................................ ................................ ...... 42 
10.2.  Reporting Procedures  ................................ ................................ ................................ .............................  42 
10.2.1.  Procedures for reporting adverse events  ................................ ................................ ........................  42 
10.2.2.  Procedure for reporting a serious adverse event  ................................ ................................ ..........  43 
10.2.3.  Withdrawal Due to an Adverse Event  ................................ ................................ .............................  43 
11. PREGNANCY  ................................ ................................ ................................ ................................ .............  44 
12. STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ .. 45 
12.1.  Sample Size and Power Consideration  ................................ ................................ ...............................  45 
12.2.  Statistical Analysis of Efficacy  ................................ ................................ ................................ .............  45 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 6 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   12.3.  Statistical Analysis of Safety Data  ................................ ................................ ................................ ....... 46 
12.4.  Interim Analysis  ................................ ................................ ................................ ................................ ....... 46 
13. QUALITY CONTROL AND QUALITY AS SURANCE  ................................ ................................ . 46 
13.1.  Protocol Amendments  ................................ ................................ ................................ ............................  46 
13.2.  Protocol Deviations, Violations and Exceptions  ................................ ................................ ...............  47 
13.3.  Training  ................................ ................................ ................................ ................................ .....................  47 
13.4.  Monitoring  ................................ ................................ ................................ ................................ ................  47 
13.5.  Data Management  ................................ ................................ ................................ ................................ ... 48 
13.6.  Quality Assurance  ................................ ................................ ................................ ................................ ... 48 
13.7.  Record Retention  ................................ ................................ ................................ ................................ ..... 48 
14. ETHICS AND GENERAL STUDY CONDUCT CONSIDE RATIONS  ................................ ....... 49 
14.1.  Institutional Review Board (IRB)/Ethics Committee (EC) ................................ ......................  49 
14.2.  Ethical Conduct of the Study  ................................ ................................ ................................ ............  50 
14.3.  Regulatory Documents  ................................ ................................ ................................ ...........................  50 
14.4.  Contractual Requirements  ................................ ................................ ................................ ....................  50 
15. APPENDICES  ................................ ................................ ................................ ................................ .............  51 
15.1.  Subject Instruction Sheet  ................................ ................................ ................................ ......................  51 
16. References  ................................ ................................ ................................ ................................ ....................  53 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 7 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
1. SYNOPSIS  
Protocol Number A -101-WART -202 Synopsis  
Protocol Number:  
 
 Protocol Title:   
A Randomized, Double -Blind, Vehicle -Controlled, Parallel Group Study of 
A-101 Topical Solution Applied Once a Week in Subjects with Common 
Warts  
Sponsor:  
 
Aclaris  
 Phase of Development:  
 
Phase 2  
Study Dru g Description:  
 
A-101 Solution ( 45%) is a hydrogen peroxide  solution  that will be supplied in a glass ampule with an 
applicator to be applied to common warts  (verruca vulgaris) on the trunk or extremities .     
 
The study drug, A -101 (hydrogen peroxide) 45% Topical Solution (hereafter referred to as A -101) is a 
colorless solution that must be stored at room temperature ( 15-25º C or 59 -77 º F).   The blinded vehicle 
solution is packaged to match the active study drug and will be stored under the same conditio ns.   
Study Objectives:  
 
Primary:  
The main objective of this study is to evaluate the clinical effect of A-101 45%  vs Vehicle  when applied 
to 1 common Target W art (verruca vulgaris) on the  trunk or extremities .  
 
Secondary : 
The secondary objectives of thi s study include:  
• Evaluate the clinical effect of A -101 45% when applied to all treated  Warts  (Target plus Non -
Target Warts)  
• Dura tion of response  in all treated Warts ( Target Warts plus Non-Target Warts ) 
• Safety of A-101 45%  
Study Design:   
This is a phase 2, randomized , multicenter  study to evaluate the safety and efficacy of A -101 4 5% vs 
Vehicle in subjects with common warts  on the trunk or extremities .  Subjects may have up to a total of 4 
treated common warts  located on their trunk  or extremities .  Inves tigator s will be required to identify  1 
Target Wart for treatment with A -101 study medication.  An additional 3 Non -Target Warts may be 
treated and followed throughout the study protocol therapy.   All identified Common  Warts will be treated 
once a week fo r 8 weeks. Subjects will be followed for 3 months after the last weekly treatment.       
 
Approximately 120  evaluable subject s will be randomized to one of 2 treatment arms in a 1: 1 ratio.  The 
duration of study participation is anticipated to be up to a m aximum of 155 days per subject.  All subjects 
will be fol lowed for at least 12 weeks after the last study medication treatment.   
 
Safety will be evaluated based on clinical laboratory studies (hematology and clinical chemistry), vital 
signs, assessment of  local skin reactions (LSRs), assessment of adverse events (AEs), and concomitant 
medication review.   
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 8 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Efficacy will be evaluated based on assessment of each Target  and Non -Target Wart  according to the 
Physician  Wart  Assessment (P WA).  Sites will be requi red to take standardized color photographs of each 
Target  and Non -Target Wart  to assist with the documentation of the location of each of the wart 
throughout the study.   
 
Number of Patients to be Enrolled:  
 
Approximately 120  evaluable subjects will be ra ndomized to the study.   
Number of Study Sites:  
 
This study will be conducted in the US only at approximately 15 treatment centers.   
Inclusion Criteria:  
Subjects must meet all of the following criteria to be considered for participation in this study.   
1. Subject is able to comprehend and is willing to sign an informed consent /assent  for participation 
in this study.  
2. Male or female ≥ 8 years old.  
3. Subject has a clinical  diagnosis of common warts . 
4. Subject has up to 1 Target Wart  and up to 3 additional Non -Target Warts  located on the  trunk  or 
extremities .  The identified Target and Non -Target Warts must meet the requireme nts as defined 
below:  
a. Each  wart must have a longest axi s that is ≥  3mm and ≤  8 mm and have a 
thickness of ≤3mm  
b. Each wart must b e a discret e lesion  
c. Each wart must be present for at least 4 weeks  
d. Not be covered with hair which, in the investigator’s opinion,  would interfere with the 
study medication treatment or the study evaluations  
e. Not be in an intertriginous fold  
f. Be the only common wart present when the circular cutout template is centered over the 
wart 
5. The Target and Non -Target Warts must have a PWA ≥ 2 . 
6. Subject chemistry and complete blood count results are within normal limits. If any of the 
laboratory values are outside normal range, the treating investigator must assess the value/s as 
NOT clinically significant and document this in the subject ’s medica l chart in order for the 
subject to be eligible for randomization.    
7. Woman of childbearing potential  (WOCBP) must have a negative urine pregnancy test within 14 
days of the first application of study drug and agree to use an active method of birth control for 
the duration of the study.  
8. Subject is non -pregnant and non -lactating.  
9. Subject is in good general health and free of any known disease state or physical condition which, 
in the investigator’s opinion, might impair the evaluation of any Target or Non -Target Warts  or 
which exposes the subject to an unacceptable risk by study participation.   
10. Subject is willing and able to follow all study instructions and to attend all study visits.  
 
Exclusion Criteria:  
Subjects are excluded from this study if any 1 or more of the following criteria is met:  
1. Subject has clinically atypical warts on the trunk or extremities . 
2. Subject is immunocompromised (e.g ., due to chemotherapy, systemic steroids, genetic 
immunodeficiency, transplant status, etc .). 
3. Subject has per iungual , subung ual, genital, anal, mosaic, plantar, flat, or filiform wart  as a Target 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 9 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   or Non -Target Wart.  
4. Subject has a history of Human Immunodeficiency Virus (HIV) infection . 
5. Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to Visit  2 
6. Subject has used any of the following intralesional therapies within the specified period prior to 
Visit 2 
• Immunotherapy (e.g., Candida  antigen, mumps antigen, Trichophyton  antigen); 8 weeks  
• Anti-metabolite therapy (e.g., bleomycin, 5 -fluorou racil); 8 w eeks 
7. Subject has used any of the following systemic therapies within the specified period prior to Visit 
2: 
• Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept,  infliximab); 
16 weeks  
• Glucocorticoster oids (inhaled and intra -nasal steroid s are permitted); 28 days  
8. Subject has used any of the following topical therapies within the specified period prior to Visit 2 
on, or in a proximity to any Target  or Non -Target  Warts , that in the investigator’s opinion 
interferes with the study medication treatment or the study assessments:  
• LASER, light or other energy based therapy ( e.g., intense pulsed light [IPL], photo -
dynamic therapy [PDT]; 180 days  
• Immunotherapy (e.g ., imiquimod, squaric acid dibutyl ester[SADBE], etc) ; 12 weeks  
• Liquid nitrogen, elect rodesi ccation, curettag e; 60 days  
• Hydrogen peroxide; 90 days  
• Anti-metabolite therapy (e.g ., 5-fluorouracil); 8 weeks  
• Retinoids; 90 days 
• Over -the-counter (OTC) wart therapies; 28 days  
9. Subject currently has or has had any of the following within the specifie d period prior to Visit 1 
on or in a proximity to any Target  or Non -Target  Warts that, in the investigator’s opinion, 
interferes with the study medication treatment or the study assessments:  
• Cutaneous malignancy; 180 days  
• Sunburn; currently  
• Pre-malignancy (e.g., actinic keratosis); currently  
10. Subject has a history of sensitivity to any of the ingredients in the study medications.  
11. Subject has any current skin disease ( e.g., psoriasis, atopic dermatitis, eczema, sun damage), or 
condition ( e.g., sunburn, excess ive hair, open wounds) that, in the opinion of the investigator, 
might put the subject at undue risk by study participation or interfere with the study conduct or 
evaluations.  
12. Participation in another therapeutic investigational drug trial in which admini stration of an 
investigational study medication occurred with 30 days prior to Visit 1.  
Duration of Treatment  
The duration of the study participation is an ticipated to be a maximum of 155  days per su bject.  The final 
visit (Visit 13 ) has a maxi mum allowa ble visit window of 7  days:  Study visits are:  
• Visit 1 (Day -13 to 0) screening  
• Visit 2 (Day 1) randomization; study medication treatment  
• Visit 3 (Day 8)  study medication treatment   
• Visit 4 (Day 15 ) study medication treatment  
• Visit 5 (Day 22 ) study medicat ion treatment  
• Visit 6 (Day 29 ) study medication treatment  
• Visit 7  (Day 36 ) study medication treatment  
• Visit 8 (Day 43 ) study medication treatment  
• Visit 9 (Day 50)  study medication treatment  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 10 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   • Visit 10 (Day 57)  follow up evaluations, no Target or Non -Target Wart retreatment  
• Visit 11 (Day 78)  follow up evaluations, no Target  or Non -Target Wart retreatment  
• Visit 12 (Day 106)  follow up evaluations, no Target  or Non -Target  Wart retreatment  
• Visit 13 (Day 134)  follow up evaluations, no Target  or Non -Target  Wart retr eatment; end of 
study  
Criteria for Evaluation  
Efficacy:  
The investigator will evaluate the severity of each Target and No n-Target Wart using the Physician  Wart  
Assessment ( PWA ) 
 
Safety:  
Safety will be evaluated by following adverse events,  clinical labora tory exams,  vital signs, concomitant 
medications, as well as through skin examinations and general physical exams.   
 
Study Drug Administration  
 
Study drug medication will be applied to each Target  and Non -Target  Wart  meeting the requirements  for 
treatmen t/retreatment  during Visits 2 through 9.  The study drug will be applied by the subject in the 
presence of the treating physician or a  member of the investigational site staff  who is a trained healthcare 
professional . Subjects between the ages of 8 and 17 years of age will have their A -101 study medication 
applied by the investigational research staff.      
 
Study medication must be applied to each of the Target  and Non -Target  Wart s for approximately 15 
seconds. The treated warts  must remain undisturbed for  approximately 15 seconds.  This treatment cycle 
may be repeated up to 3 times to each Target and Non -Target Wart.    
 
Statistical Methods  
 
Efficacy Analysis  
The primary efficacy analysis will be  a comparison between treatment groups based on the  mean cha nge 
in Target Wart  PWA from Baseline (Visit 2) to Visit 10, using Analysis of Covariance with Baseline 
PWA as the covariate.  Secondary efficacy analyses will include comparisons between treatment groups 
based on the  following: the  proportion of subjects w ith the Target Wart Clear (PWA = 0) at Visit 10 using 
Fisher’s Exact Test ; the proportion of subjects with all treated warts Clear at Visit 10 using a Cochran -
Mantel -Haenszel test strati fied by number of treated warts;  and the mean of per -subject percent ages of all 
treated w arts that are clear at Visit 10  using Analysis of Variance .  Durability of response in the Active 
treatment group will be evaluated by calculating the proportion of those treated warts achieving a PWA  
status of Clear at Visit 10  which  continue to  maintain a PWA  status of Clear at Visit 13.  This analysis 
will be performed separately for Target Warts, and for all treated warts.  The 95% confidence limits 
around the calculated proportions will also be calculated in order  to estimate the population lower limit 
value of the observed sample proportions.  
 
Safety Analysis  
Safety endpoints for adverse events (AEs) include the following:  incidences of all treatment -emergent 
AEs (TEAEs) and all serious AEs (SAEs); by severity, by relationship to s tudy drug and discontinuation 
of patients from study due to AEs.  Safety endpoints for AEs, clinical laboratory tests, vital signs, and 
physical examinations and local skin reactions will be specified in the statistical analysis plan (SAP).  All 
safety end points will be summarized using descriptive statistics.   
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 11 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
Abbreviation  Term  
AE  Adverse Event  
ANCOVA  Analysis of Covariance  
°C Degrees Centigrade  
CMH  Cochran -Mantel -Haenszel  
CRA  Clinical Research Asso ciate  
CRO  Contract Research Organization  
CS Clinically Significant  
e.g.  for example,  (Latin;  exempla gratia ) 
EC Ethics Committee  
eCRF  Electronic Case Report Form  
°F Degrees Fahrenheit  
FDA  Food and Drug Administration  
5FU 5 Fluorouracil  
G Gram  
GCP Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
H2O2 Hydrogen Peroxide  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
i.e.  that is (Latin;  id est ) 
IPL Intense Pulsed Laser  
IRB Institutional Review Board  
ITT Intent to Treat  
LOCF  Last Observation Carried Forward  
LSR Local Skin Reactions  
MedDRA  Medical Dictionary for Regulatory Activities  
mL Milliliter  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 12 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Abbreviation  Term  
Mm Millimeter  
NCS Not Clinically Significant  
OTC Over -The-Counter  
PDT  Photodynamic Therapy  
PP Per Protocol  
PWA  Physician Wart Assessment  
SAE  Serious Adverse Event  
SI Subject Identifier  
SK Seborrheic Keratosis  
SOP Standard Operati ng Procedure  
US United States  
WOCBP  Women of childbearing potenti al 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 13 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   2. INTRODUCTION  
2.1. Summary  
Warts are benign proliferations of the skin and mucosa that are caused by infection of 
keratinocytes by subtypes of the human papilloma virus (HPV) family.  Cutaneous HPV 
subtypes are a subset of this large group of the DNA papill omavirus family that is capable of 
infecting humans and causing cutaneous lesions. HPVs are ubiquitous in the environment and 
infection occurs most commonly through direct contact with individuals who harbor the virus 
clinically (eviden t lesions) or subcli nically, indirectly through exposure to contaminated 
surfaces, or even by autoinoculation of virus from individual lesions to adjacent uninfected 
skin. Cutaneous manifestations of HPV infection include common warts (verruca vulgaris), 
palmar and plantar wa rts, mosaic warts, flat warts, and butcher’s warts. Common warts are 
generally small, rounded, hyperkeratotic, exophytic dome -shaped papules or nodules and are 
typically associated with HPV subtypes 1, 2 or 4 though other subtypes are reported. Lesions 
are most commonly located on the fingers (including periungual and subungual regions), dorsal 
surfaces of the hands, and sites prone to trauma ( e.g., knees, elbows), but commonly occur at 
virtually any other anatomical location, potentially spreading by autoi noculation from the 
finger/hand  lesions.  
In immunocompetent individuals, many common cutaneous warts (up to 2/3rds in some 
reports) may spontaneously resolve in less than 2 years. However, they often persist for many 
years, may be large and/or cosmetically  unsightly ( e.g., face, hands), spread to distant 
anatomical regions by autoinoculation, be painful and/or prone to trauma, and, importantly, 
provide a significant reservoir of HPV infection in the community, placing (especially 
immunocompromised) individu als at risk for significant morbidity.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 14 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   There are currently no specific antiviral therapies available to treat cutaneous HPV infection 
and there is no FDA -approved topical treatment for cutaneous common warts. Existing 
therapies, many of which are off -label  uses of drugs approved for other indications, and many 
of which have never undergone the drug approval process, are  of unproven safety and/or 
efficacy, and are generally directed towards either the direct physical destruction of the lesions 
with locally destructive or ablative modalities such as cryotherapy, electrosurgery, curettage, 
application of acids ( e.g., salicylic acid, trichloroacetic acid); locally cytotoxic therapies, such 
as topical podophyllin, cantharidin, topical or intralesional 5 -fluorour acil, or bleomycin; topical 
immunomodulatory or immunotherapy ( e.g., topical imiquimod, intralesional candida antigen, 
topical squaric acid dibutyl ester) or lesion removal. Several of these therapies are also 
available as over -the-counter (OTC) wart thera pies in lesser exposures than used in the office 
setting ( e.g., topical salicylic acid preparations, home freezing kits). Systemic therapy with 
agents such as cimetidine, and even local occlusion with duct tape have also been anecdotally 
reported to be eff ective in some cases. While these methods may achieve cure in some cases, 
many require multiple visits to a physician’s office, and may require providers with specialized 
training and the use of expensive equipment. Such procedures can be painful, may requ ire 
anesthesia and/or analgesia, and they can be complicated by adverse cosmetic outcomes 
including scarring at the treatment site, as well as the typical post -surgical risks of bleeding and 
infection. No one therapy is consistently effective in all cases and, in fact, there is great 
variability among practitioners in the methods employed using each of these techniques with 
great variability of the  results.  
 
Hydrogen peroxide (H 2O2) is a compound that is ubiquitous in the environment. It is the simplest 
peroxide and a potent oxidizing agent commonly used in innumerable household goods including 
chlorine -free bleaches, general -purpose cleaning products, and disinfectants. Additionally, H 2O2 
has been employed as the oxidizing component in hair dyes, and has be en used in oral hygiene 
products and tooth -whitening systems for many years. In industry, it is employed in the treatment 
of wastewater. In high concentrations, it is used in bleaching paper, pulp, and textiles. Clinically, 
in addition to its use as an ora l topical agent noted above, H 2O2 is widely employed at low 
concentrations ( e.g., 3%-6%) as a wound irrigant and topical antiseptic/disinfectant, and has been 
in use medicinally since its introduction into clinical practice by Richardson in 1858.  (Schumb 
WC 1955)  (Chan HP 2008)  (Richardson, On Peroxide of Hydrogen, or Ozone, or Water as a 
Remedy: Continued from a Research Commenced in the Year 1858 1891)  (Richardson, On 
Peroxide of Hydrogen, or Ozone, or Water, as a Remedy: Continued from Research Commence d 
in the Year 1858 1891)  (Richardson, On the Introduction of Peroxide of Hydrogen as a Medicine 
1866)  (Watt BE 2004 )(Zonios 2007) . 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 15 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   H2O2 is an important oxidizing agent in biological systems. The local deleterious effects of 
reactive oxygen species on the  skin are mitigated by the presence of a complex antioxidant 
defense system that includes, enzymes such as catalase, glutathione peroxidase, superoxide 
dismutase, thioredoxin reductase, lipoamine, lipid peroxidase and others, as well as non -
enzymatic compo nents including ascorbic acid, urates and uric acid, tocopherol, glutathione, 
ubiquinones, ubiquinol and other water -soluble groups.  The local application of supra -
physiologic concentrations of H 2O2 may overwhelm the antioxidant defense systems in the ski n, 
allowing H 2O2 to act not only through its direct oxidation of organic tissues, generation of 
reactive oxygen species, and local lipid peroxidation, but also by the generation of local 
concentrations of O 2 that are toxic to the abnormal lesional (seborrh eic keratosis) cells.  
 
An investigator -initiated, single -site, double -blind, vehicle -controlled, parallel -group proof -of-
concept trial: “A randomized, double -blind, vehicle -controlled, parallel group study of hydrogen 
peroxide solution in adult subjects wi th common warts of the hand (WART -01), was conducted 
utilizing once weekly applications (maximum of four applications) of A -101 (hydrogen 
peroxide) 40% topical solution or placebo (vehicle) topical solution to investigate the potential 
utility of a 40% hyd rogen peroxide topical solution for the treatment of common warts on the 
hands. A total of 15 subjects received 4 study medication applications. One subject achieved 
complete clearance of the Target Wart during the investigation, and data from this pilot s tudy 
demonstrated a statistically significant trend towards clearing warts in the A -101 40% group 
when compared with the vehicle. It was the Investigator’s opinion that “1 or 2 additional 
treatments may clear the warts as most A -101 40% treated warts were “Near Clear” at the end of 
the four -week study”. The administration of A -101 40% over four applications one week apart 
showed no untoward effects and the treatment was well tolerated by all subjects. The data and 
clinical observations suggest that a larger  study allowing greater than four drug applications and 
evaluating additional doses of A -101 topical solution are  warranted.  
 
2.2. Study Rationale   
A phase 2 clinical trial was conducted in which subjects were randomized to receive A -101 40%, 
A-101 45% or Vehic le for the treatment of common warts.  Study A -101-WART -201 
randomized a total of 98 subjects with a clinical diagnosis of common warts.  Subjects received 
up to 8 weekly treatments with A -101 study medication.   
The primary and secondary efficacy endpoint s of the mean change from baseline to Visit  10 on 
the Physician Wart Assessment (PWA) and the proportion of PWA responders at Visit 10, which 
was defined as target warts judged to be clear or to be clear or mild, demonstrated superiority of 
A-101 45%, but not 40%, versus vehicle.   
Both concentrations of A -101 evaluated were well tolerated. The only TEAEs considered to be 
treatment -related were application site pain for 2 subjects (all events were considered to be mild 
and resolved on the same day without i ntervention) and chlamydial infection for 1  subject. There 
were no clinically significant changes during the study in laboratory evaluations or vital signs.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 16 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   A-101 solution 45% demonstrated superiority versus the matching A -101 solution vehicle (and 
A-101 4 0%) in physician evaluations of efficacy in treating target warts on the trunk or 
extremities  and was well tolerated with occurrence of local skin reactions that were generally 
transient.   Based on these results a phase 2 study comparing A -101 45% vs Vehic le is warranted.   
 
3. OBJECTIVES  
3.1. Study Objectives  
3.1.1.  Primary Objective  
The primary objective of this study is to evaluate the  effectiveness of A-101 45% compared to 
vehicle when applied to 1 common t arget  wart on the trunk or extremities.     
3.1.2.  Secondary Objectiv e 
The secondary objectives of this study include:  
• Evaluate the clinical effect of A -101 45% when applied to all treated warts (Target plus Non -
Target Warts)  
• Dura tion of response  in all treated warts (Target Warts plus Non -Target Warts)  
• Safety  of A-101 45% 
4. STUDY DESIGN  
This is a phase 2, randomized, multi -center, study designed to evaluate the safety and efficacy of 
A-101 45% compared to Vehicle in subjects with common warts on the trunk or extremities .   
 
During the study, the investigator will identify 1 eligible Target Wart  and up to 3 additional Non -
Target Warts  on each subject on the trunk  or extremities .  All Target and Non -Target Warts  will 
be treated weekly for 8 weeks.    
 
Subjects will be required to complete a total of 13 study visits.  The protoco l defined study visits 
are: 
• Visit 1 (Day -13 to 0) screening  
• Visit 2 (Day 1) randomization; study medication treatment  
• Visit 3 (Day 8)  study medication treatment   
• Visit 4 (Day 15 ) study medication treatment  
• Visit 5 (Day 22 ) study medication treatment  
• Visit  6 (Day 29 ) study medication treatment  
• Visit 7  (Day 36 ) study medication treatment  
• Visit 8 (Day 43 ) study medication treatment  
• Visit 9 (Day 50) study medication treatment  
• Visit 10 (Day 57) follow up evaluations, no Target or Non -Target Wart retreatment  
• Visit 11 (Day 78) follow up evaluations, no Target or Non -Target Wart retreatment  
• Visit 12 (Day 106) follow up evaluations, no Target  or Non -Target Wart retreatment  
• Visit 13 (Day 134) follow up evaluations, no Target or Non -Target Wart retreatment; end of 
study 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 17 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Refer to Section 6 for a complete list of protocol required study assessments.   
 
A completed evaluable subject is a subject that misses no more than 3 treatment visits, completes 
Visit 10 and  Visit 13 (end of study visit),  has had all Target Warts  assessed at these visits and has 
not had a protocol violation documented during the study . 
4.1. Number of Subjects  and Study Centers  
Approximately 120 evaluable  subjects will be randomized to one of  two treatment arms a t 
approximately 15 investigational centers in the US.  
 
4.2. Duration of Study  
The anticipated time for study enrollment is 3 months. The duration of study participation is 
anticipated to be a maximum of 155  days per subject.  Subjects will have a total of 13  study 
visits.  The maximum anticipated duration for the study is approximately 8 months.  
 
5. STUDY ENTRY CRITERIA  
5.1. Inclusion Criteria  
Subjects must meet all of the following criteria to be considered for participation in this study.   
1. Subject is able to comprehend and is willing  to sign an informed consent /assent  for 
participation in this study.  
2. Male or female ≥ 8 years old.  
3. Subject has a clinical diagnosis of common warts.  
4. Subject has up to 1 Target Wart  and up to 3 additional Non -Target Wart s located on the  
trunk or extremities.  The identified Target and Non -Target Warts must meet the 
requireme nts as defined below:  
a. Each  wart must have a longest axi s that is ≥  3mm and ≤  8 mm and have a 
thickness of ≤3mm  
b. Each wart must be a discret e lesion  
c. Each wart must be present for at least 4 weeks  
d. Not be covered with hair which, in the investigator’s opinion,  would interfere 
with the study medication treatment or the study evaluations  
e. Not be in an intertriginous fold  
f. Be the only common wart present when the circular cutout template is centered 
over the wart  
5. The Target and Non -Target Warts must have a PWA ≥ 2  
6. Subject chemistry and complete blood count results are within normal limits. If any of the 
laboratory values are outside normal range, the treating investigator must assess the 
value/s as NOT clinically significant and document this in the subject’s medical  chart in 
order for the subject to be eligible for randomization.   
7. Wom en of childbearing potential (WOCBP) must have a negative urine pregnancy test 
within 14 days of the first application of study drug and agree to use an active method of 
birth control f or the duration of the study.  
8. Subject is non -pregnant and non -lactating.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 18 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   9. Subject is in good general health and free of any known disease state or physical 
condition which, in the investigator’s opinion, might impair the evaluation of any Target 
and Non -Target Warts or which exposes the subject to an unacceptable risk by study 
participation.   
10. Subject is willing and able to follow all study instructions and to attend all study visits.  
5.2. Exclusion Criteria  
Subjects are excluded from this study if any 1 or more  of the following criteria is met:  
1. Subject has clinically atypical warts on the trunk or extremities.  
2. Subject is immunocompromised (e.g ., due to chemotherapy, systemic steroids, genetic 
immunodeficiency, transplant status, etc.)  
3. Subject has periungual , sub ungual, genital, anal, mosaic, plantar, flat, or filiform wart  as 
a Target or Non -Target Wart  
4. Subject has a history of Human Immunodeficiency Virus (HIV) infection  
5. Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to Visit 2 
6. Subje ct has used any of the following intralesional therapies within the specified period 
prior to Visit 2 
a. Immunotherapy (e.g., Candida  antigen, mumps antigen, Trichophyton  antigen); 8 
weeks  
b. Anti-metabolite therapy (e.g., bleomycin, 5 -fluorouracil); 8 weeks  
7. Subject has used any of the following systemic therapies within the specified period prior 
to Visit 2: 
a. Immunomodulatory/immunosuppressant therapy (e.g., etanercept, 
alefacept,infliximab); 16 weeks  
b. Glucocorticosteroi ds (inhaled and intra -nasal steroids are per mitted); 28 days  
8. Subject has used any of the following topical therapies within the specified period prior 
to Visit 2 on, or in a proximity to any Target  or Non -Target  Warts, that in the 
investigator’s opinion interferes with the study medication treatment  or the study 
assessments:  
a. LASER, light or other energy based therapy (e.g., intense pulsed light [IPL], 
photo -dynamic therapy [PDT]; 180 days  
b. Immunotherapy (e.g ., imiquimod, squaric acid dibutyl ester[SADBE], etc .) 12 
weeks  
c. Liquid nitrogen, electrodesicca tion, curettag e; 60 days  
d. Hydrogen peroxide; 90 days  
e. Anti-metabolite therapy (e.g ., 5-fluorouracil); 8 weeks  
f. Retinoids; 90 days  
g. Over -the-counter (OTC) wart therapies; 28 days  
9. Subject currently has or has had any of the following within the specified period prior to 
Visit 1 on or in a proximity to any Target  or Non -Target  Warts  that, in the investigator’s 
opinion, interferes with the study medication treatment or the study assessments:  
a. Cutaneous malignancy; 180 days  
b. Sunburn; currently  
c. Pre-malignancy (e.g. , actinic keratosis); currently  
10. Subject has a history of sensitivity to any of the ingredients in the study medications.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 19 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   11. Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun 
damage), or condition (e.g., sunburn, excessive hair,  open wounds) that, in the opinion of 
the investigator, might put the subject at undue risk by study participation or interfere 
with the study conduct or evaluations.  
12. Participation in another therapeutic investigational drug trial in which administration of 
an investigational study medication occurred with 30 days prior to Visit 1.  
 
5.3. Removal of Patients from Study Therapy  
A subject may be removed from the study therapy for a variety of reasons, including:  
• Unacceptable adverse event  
• Subject unwilling or ref usal to continue with the protocol defined study visits and/or 
consent /assent  withdrawal for study participation  
• Change in compliance with an inclusion/exclusion criteria  
• Use of a p rohibited medication (through Visit 13 ) 
• Pregnancy  
• General or specific chang es in the subjec t’s condition that render the subject  unacceptable 
for further treatment in this study in the judgement of the investigator . 
 
If a subject is to be withdrawn from the study, the Aclaris Therapeutics, Inc. study monitor or 
designee must be i nformed with in 24 hours of the decision to remove the subject from the study.   
 
The study may be discontinued at the discretion of Aclaris Therapeutics, Inc.  Some examples of 
reasons for discontinuation are the occurrence of the following:   
• Increased fr equency, severity or duration of known AEs  
• Medical, regulatory or ethical reasons affecting the continued performance of the 
study  
• Difficulties in the recruitment of subjects.  
   
5.4. Withdrawal Procedures  
If a subject withdraws from the study prior to Visit 13, the reason for and the date of withdrawal 
from the study must be recorded on the eCRF.  If the reason for withdrawal is an adverse even t 
or a clinically significant abnormal laboratory test result, monitoring of the subject will continue 
until the even t has resolved or stabilized, until the patient is referred to the care of a local health 
care professional, or until a determination of a cause unrelated to the study drug or study 
procedure is made.   
5.5. Subject  Replacement  
If a subject is randomized to the s tudy but does not receive a dose of study drug, then the subject 
will be replaced.   
 
Subjects that are determined to be screen failures may be rescreened for the study and if 
determined to be eligible for the study they may be randomized using the same su bject identifier.    
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 20 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   5.6. Subject Identifier (SI)  
The investigator or designee will assign a unique five -digit subject identifier (SI) to each subject 
at Visit 1.  
 
The SI format will be NN -NNN where the first 2 digits are the investigational center site number 
(using leading zeroes , as appropriate). The final 3 digits are the subject number and must be 
assigned in ascending numerical order, without omitting or repeating any number, starting with 
001 at each investigational center. For example, the SI for the sec ond subject that signs an 
informed consent /assent  at site number 04 would be 04 -002.  
 
The subject will be identified using the SI in all study documentation for the duration of the 
study.  
 
6. STUDY PROCEDURES  
The schedule of study activities (including asses sments, tests, exams, disease assessments, and 
study drug administration) beginning with screening and continuing through the end of study are 
outlined in  Table 1.  A written, signed informed consent form (ICF) /assent  must be obta ined 
from each subject prior to performing any study related procedure ( e.g., vital signs, clinical 
laboratory sampling, urine pregnancy test or photography).   
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 21 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Table 1:  Study Procedures  
Visit  V1 
Screening  V2 V3 V4 V5 V6 V7 V8 
 V9 V10 V11 V12 V13 
Treatment Day  -13 to 0  1 8 15 22 29 36 43 50 57 78 106 134 
 Treatment Window  N/A N/A ±1 day  ±4 days  ±4 
days ±4 
days ±4 days  ±4 
days ±4 
days +4 
days ±7 
days ±7 
days +7 
days 
Study Procedures        
Informed Consent /Assent  X             
Inclusion 
Criteria/Exclusion Criteria  X X1            
Subject Identifier  X2             
Medical 
history/demographics  X             
Fitzpatrick Skin Type 
Assessment  X3             
Vital Signs  X4        X    X 
Prior 
Medications/Therapies  X5             
Clinical Chemistry and 
CBC6 X        X    X 
Urine Pregnancy Test7 X X       X    X 
Target Wart  Identification8 X             
Physician’s Wart  
Assessment9 X X X X X X X X X X X X X 
Target Wart  Dimensions10 X X X X X X X X X X X X X 
Standardized 
Photog raphy11 X X  X     X X   X 
Subject Randomization   X12            
Local Skin Reactions   X13 X13 X13 X13 X13 X13 X13 X X X X X 
Study Medication 
Application14  X X X X X X X X     
Weighing of Study 
Medication Applicators15  X X X X X X X X     
Subject In structions  X X X X X X X X X X X X  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 22 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Concomitant therapies16  X X X X X X X X X X X X 
Adverse Events17  X X X X X X X X X X   
1Subject inclusion/exclusion criteria will be re -assessed prior to randomization during Visit 2.  
2Investigational sites will as sign a unique five -digit subject identifier to each subject at Visit 1. This subject identifier will be used in all study documentation for 
the duration of the study.   
3Each subject’s skin must be assessed during Visit 1 using the Fitzpatrick Skin Type As sessment. Refer to Section  9.5.1  for the scale.  
4Vital signs [including temperature, pulse, respiratory rate, blood pressure, height and weight (Visit 1 only)] will be measur ed by a qualified staff member at Visit 
1, Visit 9 a nd Visit 13 .   
5Prior medications/therapies will be collected for a time -period of 13 days prior to Visit 2.  Refer to Section 7.8 for a list of permitted and restricted concomitant 
medications.    
6A complete blood count (incl uding hematocrit, hemoglobin, platelet count, red blood cell count  and morphology , white blood cell count and differential 
(absolute and %) including basophils, eosinophils, lymphocytes, monocytes and neutrophils and a clinical chemistry panel incl uding al bumin, alkaline 
phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), bicarbonate, calciu m, chloride, creatinine, glucose, 
lactate dehydrogenase (LDH), phosphorus, potassium, sodium, total bilirubin, tota l protein, and uric acid.   
7 Woman of child bearing potential will be required to have a urine pregnancy test at Visit 1, at Visit 2 prior to randomizatio n, Visit 9 and Visit 13 . 
8The treating investigator will identify 1 Target Wart and up to 3 additiona l Non -Target Warts  on the trunk  and extremities .   
9 The investigator will use the Physician  Wart Assessment (PW A) to assess each Target  and Non -Target Wart s.  The investigator must assess the Target  and 
Non-Target  Warts  prior to application of the study m edication  at Visit 2 -Visit 9 .  In order to be eligible for randomization at Visit 2, the subject must have a 
PWA grade ≥ 2.   
10 The investigator will measure the dimensions (longest diameter and thickness) of the Target and Non -Target Warts  at Visit 1 and prior to randomization at 
Visit 2.  In order for the subject to be randomized at Visit 2 each Target and Non -Target Wart m ust have the specific dimensions  outlined in Section 8.1. At 
Visits 3 -13 the investigator will measure the diameter of each Target and Non -Target Wart.    
11 At Visits 1, Visit 2 (prior to study medication applicati on), Visit 4 prior to study medication application, Visit 9, Visit 10 and at Visit 13, a qualified 
investigational center staff member will take a photograph of each Target and Non -Target Wart using the Aclaris supplied camera.  All photographs will be sen t 
to a central imaging laboratory.   
12 Subjects will be randomized at Visit 2 prior to application of study medication.  Investigational study staff will re -confirm subject eligibility prior to 
randomization.   
13 The investigator and subject will assess each Target Wart  for local skin reactions associated with irritation  at Visits 2 -13.  At Visit 2 -Visit 9 , the investigator 
and subject will assess the Target  and Non -Target  Warts  for LSRs prior to the application of the study medication .  The subject will assess LSRs 10 (±4) minutes 
after the application of A -101 study medication and the investigator will assess for LSRs 20 (± 4) minutes after application of A -101 study medication.  Refer to 
Section 9.1 for the c omplete list of Local Skin Reaction signs and symptoms.   
14The investigator will apply the A -101 study medication to subject  8 to 17 years of age.  Subjects 18 years of age and older will appl y their A -101 study 
medi cation in the presence of the treating physician or a member of the investigational study  staff that has been trained on the protocol .  All Target and Non -
Target Warts  will be treated with study medication following randomization at Visit 2.  If a Target or Non -Target Wart  meets the criteria fo r re-treatment as 
defined in Section 7.6 the lesion will be re -treated at Visit 3 -9.  Following application of study medication, subjects must NOT wash/submerge the Target  or 
Non-Target Warts  for at least 6 hours and they must NOT apply any topical products to the Target  or Non -Target  Warts  for at least 6 hours.   
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 23 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   15Sites will be required to weigh all A -101 study medication applicators before and after treatment and document the weight of each applicator in the subject’s 
eCRF.   
16All concomitant therapies including (topical and oral) prescription medications, over the counter medications and natural sup plements and non -drug therapies 
including chiropractic, physical therapy, and energy based therapy must be documented in the sub ject CRF.  Subjects must not apply any topical products (e.g. , 
moisturizers, sunscreen, etc.) to their Target or Non -Target Warts  within 12 hours prior to any study visit .   
17The reporting period for Serious Adverse Events (SAEs) begins when the subject s igns the informed consent  and continues through Visit 11.  Refer to Section 
10.1.2  for instructions on the reporting of SAEs.  Non -serious clinical adverse events will be collected following the application of t he study medication at Visit 
2. Non -serious adverse events that occur between the time of consent and study medication application will be documented as medical history.   All safety 
reporting (AEs and SAEs) will conclude at Visit 11 (approximately 28  days after last study medication application) except for clinical adverse events related to 
local skin reactions.      
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 24 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   7. STUDY TREATMENT  
7.1. Investigational Study Medication  
The study medications for the study are A -101 45% , and matching Vehicle .  All study medicat ions 
are solutions that are water -clear, colorless solutions which  are indistinguishable in physical 
appearance .   
 
Table 2 Study Medication Information  
Study Medication 
Name  A-101 45%  Vehicle  
Manufacturer  James Alexander Corporati on, Blairstown NJ  
A-101 concentration 
(%) 45 0 
Pharmaceutical Form  Solution  
Storage Conditions  15ºC to 25ºC or 59ºF to 77ºF protected from excessive heat, open flame 
and combustibles, out of direct sunlight and in a well -ventilated, dry 
area*  
Route  Topical 
Frequency  A-101 Study Medication will be applied once a week for 8 weeks.   
Application  Safety glasses and nitrile or vinyl examination gloves must be worn 
during the application process.  Latex gloves are prohibited.   
Duration of 
Administration  Apply study medication to each Target /Non-Target Wart  for 
approximately 15 seconds.  Allow each Target/ Non-Target Wart  to 
remain undisturbed for approximately 15 seconds.  Repeat the 
application/waiting cycle until the study medication has been applied to 
each Target and Non -Target Wart  up to  3 times.   
Activated Applicators  Activated applicators are stable for 4 hours at room temperature ( 15ºC 
to 25ºC or 59ºF to 77ºF ) 
*Excursions from these temperature ranges must be reported to Ac laris.   
 
7.2. Subject Random ization  
Prior to the start of the study, Aclaris Therapeutics, Inc./designee will generate a randomization list 
that will be provided to the assigned clinical packaging organization for study medication labeling.   
 
The randomization list will be stored w ith limited access to designated personnel for study 
medication labeling.      
 
Subjects will be randomized to the study in a 1: 1 ratio.  Subjects will be randomized at Visit 2 
following re -confirmation of subject eligibility.    
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 25 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   7.3. Study m edication packaging , storage and dispensing  
A-101 45 % and matching Vehicle will be provided by Aclaris Therapeutics, Inc. and labelled 
according to the local law and legislation.   
 
The study medication will be packaged in single use applicators.  Each single -use applicator 
consists of a crushable glass ampoule that contains 2.2 milli liters (mL) of study medication that 
provides for at least 1.3 mL of study medication available for treatment.  The ampoule is provided 
inside a sealed polyethylene tube with a flocked, doe foot applicator on one end.   
 
Each subject kit will be packaged with 10 treatment applicators.  The outside of e ach subject kit will 
be labelled with a two part, three panel, double blind label.  One part (one -panel) of the label 
remains attached to the Subjec t Kit, the other part (two -panel tear -off) is separated and attached to 
the subject’s Label Page CRF when the subject is randomized.    
 
A-101 study medication must be stored in a location where there is limited access to the 
investigational study medicatio n at room temperature (15ºC to 25ºC or 59ºF to 77ºF ) protected from 
excessive heat, open flame and combustibles, out of direct sunlight and in a well -ventilated, dry 
area.    
 
Investigational study medication supplies are only to be used for subjects proper ly consented and 
randomized  to this study.   
 
7.4. Drug Accountability  
The investigator or designee will maintain an accurate record of the receipt of the study medications 
as shipped by Aclaris Therapeutics, Inc. (or designee), including the date received and  the condition 
of the study medications. One copy of this receipt will be returned to Aclaris Therapeutics, Inc. (or 
designee) when the contents of the study medication shipment have been verified and one copy 
maintained in the study file. In addition, an accurate study medication disposition record will be 
kept, specifying the amount dispensed for each subject and the date of dispensing. This inventory 
record will be available for inspection at any time. At the completion of the study, the original 
invento ry record will be available for review by Aclaris Therapeutics, Inc. upon request.  
   
Final drug accountability will be completed by the study monitor at the completion of the study and 
all unused study medication will be returned to Aclaris Therapeutics, Inc. drug depot  for disposal 
per Aclaris Therapeutics, Inc. (or designee’s) written instructions . 
7.5. Weighing of Study Medication Applicators  
Sites will be required to weigh each A -101 study medication applicator before all Target and Non -
Target Warts are tre ated.  The used applicators will be weighed again after all warts have been 
treated.  The weight of the applicators will be documented in the subject’s eCRF.   Sites will be 
supplied with a scale to weigh each applicator.   
 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 26 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   7.6. Study Medication Treatment  
The study medications are for external, topical use on the Target and Non -Target Warts  on the 
appropriate study subject only.  
 
The investigational center staff member must comply with the study medication storage conditions 
outlined in Section 7.1.   
 
At Visit 2, the investigational study staff will select the appropriate study medication applicator for 
treatment of a specific subject. Subject s ages 18 years of age and older  will apply the appropriately 
labeled A -101 study medicat ion to all Target and Non -Target Warts in the presence of the treating 
investigator or investigational staff that has been trained on the protocol.   Investigational study staff 
will apply A -101 study medication to subjects between the ages of 8 and 17.    
 
At Visit 3-9, any Target  or Non -Target  Wart  that has a PWA grade of >0  and ONLY Target 
Wart s or Non-Target Warts that have a P WA grade of >0 , must receive study medication 
treatment UNLESS either of the following criteria apply to the Target or Non -Targe t Wart : 
• The Target or the Non -Target Wart  has a pre-treatment LSR grade of 3 (severe) for any sign 
or symptom AND the grade has increased compared to the previous visit.  
• The Target  or the Non -Target Wart  is, in the investigator’s opinion, not appropriate f or a 
retreatment (the investigator must note the reason on the subject’s Comments CRF page).  
• The Target  or the Non -Target Wart, in the Investigator’s opinion, cannot be visualized so 
the Investigator cannot assess the PWA.   
 
Following treatment with the A -101 study medication applicator, all used applicator s must be 
disposed of in a biohazardous container.   
7.6.1.  Preparing the Study Medication for Application  
To perform a study medication treatment for Target  and Non -Target  Wart s a staff member will 
select the appropriate study medication applicator. The following instructions  outline the procedure 
for application of the study medication to the Target and Non -Target Warts :  
• Investigational Study Staff member will p repare the A -101 study medication applicator for  
all subjects, regardless of age by: 
o Washing their  hands prior to, and after completing the study medication treatments  
o Wear safety glasses and nitrile or vinyl examination gloves during the treatment; 
latex gloves are prohibited  
o Complete the study medica tion applicator label as instructed  
o Visually inspect the applicator for damage:  
▪ If the applicator appears damaged do not use it for the treatment, contact the 
study monitor for disposal instructions and select an other  unused applicator 
for treatment . 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 27 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   If the applicator is intact, proceed with the applicator preparation  process  as outlined in  
Figure 1. 
 
 
 
Step 1:  Hold the Study Medication    Step 2:  Crush the ampule in the  
applicator so that the applicator          applicator by applying pressure at  
cap is pointing up.                               the center of the barrel of the applicator . 
 
 
Step 3: Remove the cardboard   Step 4: Tap the barrel of the applicator  
sleeve.                                         to ensure the  solution is free of the  
                                                    crushed ampule.     Target Warts  should be cleaned using an 
alcohol wipe prior to application of A -101 
Solution or matching Vehicle Solution .   
 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 28 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
 
 
Step 5:  Gently remove the cap        Step 6:  Express a single drop of  
by twisting while pulling away        the Study Medication  Topical Solution  
from  the applicator.                          so that the  tip of the applicator becomes wet.  
 
Figure 1:   Diagram Showing the Process for Preparing A -101 Study Medication  
7.6.2.  Applying Study Medication to Target and Non -Target Warts  on the  Trunk and 
Extremities  
Subjects that are between the ages of 8 and 17 will have their A -101 study medication applied by 
the investigational study staff and the staff will follow the application process outlined below for all 
Target and Non -Target Warts.   
 
Subjects 18 years of age and older will apply  their A -101 study medication  to his/her identified 
Target and Non -Target Warts in the presence of the treating physician or member of the 
investigational staff.   
 
The following instructions will be used by a ll individuals applying A -101 study medication to all 
Target and Non -Target Warts:    
• Do not apply the study medications to eyes, nose, mouth, mucous membranes, or open 
wounds  
• Thoroughly cleanse the Target and Non -Target Warts  by firmly rubbing with a swab /wipe 
wetted with 70% isopropyl alcohol  
• Using firm pressure  and with the tip of the applicator held over the wart , squeez e in the 
middle of the applicator  to apply one drop of study medication onto the Target Wart.  
Using the smaller side of the applicator  tip, move the applicator around in a circular 
motion to fully saturate the lesion.  Apply the study medication for approximately 15 
seconds.   
• Minimize exposure to the surrounding normal skin  
• During the treatment process remove excess study medication fro m the surrounding skin 
using a clean absorbent wipe  
• Ensure that  each identified wart  is fully saturated  with study medication at the end of the 
~15 second application  
• Allow the treated wart to remain undisturbed for ~ 15 seconds  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 29 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   • After ~ 15 seconds repeat the  ~15 second application process  
• Repeat the application/waiting cycle until the study med ication has been applied to each 
identified Wart  up to 3 times.  
 
Document the number of times each identified wart is treated during a treatment Visit.  
After all ident ified warts  have been treated , the subject must be instructed not to disturb any of the 
treated warts u ntil just prior to the post -application LSR evaluation .    
 
Just prior to the post -application LSR evaluation the investigational study staff should absorb any 
remaining A-101 study medication and dry the Target and Non -Target Wart s and the surrounding 
skin without wiping or  rubbing  
 
It is acceptable to treat multiple Target /Non -Target Warts  at the same time if, in the investigator’s 
opinion, it is practic al without exposing non -lesional skin to the study medication . 
 
 
7.7. Dose modification  
If a subject refuses to allow a study medication initial treatment or retreatment the investigator must 
report the visit number, visit date, Target Wart  number(s) the subjec t refused to allow treatment for 
and the reason for the refusal in the subject’s  CRF .  
 
If the subject’s refusal is associated with an AE, the investigator must also report the event on the 
appropriate CRF .  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 30 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   7.8. Previous and Concomitant Therapies  
7.8.1.  Previous ther apies  
During Visit 1, the investigator or designee will question the subject to ensure they have not used 
any excluded therapies  within the specified period prior to Visit 1 to any of the Target or Non -
Target Wart s: 
 
• Intralesional Therapy  
o Immunotherapy (e. g., Candida  antigen, mumps antigen, Trichophyton  antigen) 8 
weeks  
o Anti-metabolite therapy ( e.g., bleomycin, 5 -fluorouracil); 8 weeks  
• Systemic Therapy  
o Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept, 
infliximab); 16 weeks  
o Glucocortic o-steroi ds (inhaled and intra -nasal steroids are permitted); 28 days  
• Topical Therapy  
o LASER (e.g., pulsed -dye laser [PDL], light (e.g. , intense pulsed light [IPL], 
photodynamic therapy [PDT], other energy based therapy); 180 days  
o Immuno -therapy (e.g. , imiqu imod, squaric acid dibutyl ester [SADBE], etc .); 12 
weeks  
o Anti-metabolite therapy (e.g ., 5-fluorouracil); 8 weeks  
o Retinoids; 90 days  
o Liquid nitrogen, electrodesiccation, curettage; 60 days  
o Over -the-counter (OTC) wart therapies; 28 days  
 
7.8.2.  Concomitant therapi es 
Concomitant therapies are any new or existing therapy received from Visit 1 until discharge from 
the study.  
 
Concomitant therapies include drug ( e.g., prescription, over -the-counter [OTC]) and non -drug ( e.g., 
chiropractic, physical therapy, energy -based treatments) therapies. Subjects will refrain from using  
any prohibited therapies  in compliance with the inclusion/exclusion criteria. Subjects should refrain 
from changing the use of any concomitant therapies during the study.  
 
All new or modified conco mitant therapies used during the study must be recorded  in the subject 
CRF . 
 
7.8.3.  Prohibited therapies  
During the course of this study, subjects are prohibited from using the following treatment therapies  
to treat any of the Target or Non -Target Warts : 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 31 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   • Intrale sional Therapy  
o Immunotherapy (e.g. , Candida  antigen, mumps antigen, Trichophyton  antigen)  
o Anti-metabolite therapy (e.g ., bleomycin, 5 -fluorouracil);  
• Systemic Therapy  
o Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept, 
infliximab);  
o Glucocortico -steriods (inhaled and intra -nasal steroids are permitted);  
• Topical Therapy  
o LASER (e.g., pulsed -dye laser [PDL], light (e.g. , intense pulsed light [IPL], 
photodynamic therapy [PDT], other  energy based therapy);  
o Immuno -therapy (e.g. , imiquimod,  squaric acid dibut yl ester [SADBE], etc .);  
o Anti-metabolite therapy  (e.g., 5-fluorouracil);  
o Retinoids;  
o Liquid nitrogen, electr odesiccation,  curettage;  
o Over -the-count er (OTC) wart therapies;  
  
The investigator should notify the Medical Monitor immediat ely if any prohibited therapies are 
required to ensure subject safety.  
 
Starting with Visit 2, subjects must not apply any topical products ( e.g., moisturizers, sunscreens, 
etc.) to their Target or Non -Target Warts  within 12 hours prior  to any study visit (Note: routine 
cleansing products are allowed).  
 
After the completion of any study visit where a study medication treatment was performed subjects 
must NOT wash/submerge  the Target or Non -Target Wart s for at least 6 hours  and must not apply 
any topical pro ducts to the Target or Non -Target Warts  for at least 6 hours . 
 
7.9. Breaking the Blind  
The blind may be broken  ONLY in the event of a medical emergency, in which knowledge of the 
study medication identity is critical to the management of the subject’s course of  treatment.  Before 
breaking the blind the investigator should determine that the information is necessary.  In many 
cases, particularly when the emergency is clearly not study medication -related, the problem may be 
effectively managed by assuming that the  subject is receiving an active study medication without 
the need for unblinding.   
 
If deemed necessary to break the blind for a study subject, attempt to contact the Medical Monitor 
to obtain permission to break the blind of a particular subject .  If it is not possible to contact the 
Medical Monitor beforehand, contact her/him as soon as possible after breaking the blind for a 
subject.  
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 32 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   To identify a subject’s study medication, locate the second panel of the tear -off label from the 
Subject Kit attached t o the subject’s Label Page CRF and follow the instructions on the label.  
Record the date of un -blinding, the reason for the un -blinding and the initials of investigational 
center staff member who performed the un -blinding on the subject’s Label Page CRF.   
 
At the end of the study, the original Label Page CRFs will be returned to Aclaris Therapeutics with 
a photocopy place d in the investigator’s study file.  The or iginal Label Page CRFs will be available, 
upon request, to the site if needed to respond to a  regulatory inspection .   
 
8. ASSESSMENTS OF CLINICAL EFFICACY  
8.1. Target  and Non -Target Wart Identification  
At Visit 1, the investigator will identify one Target Wart and up to 3 additional Non-Target Warts  
on the  trunk  or extremities  for each subject for treatm ent and evaluation.  
 
For this study,  the trunk  and extremities are defined as:  
• The front and back of the torso from the clavicle to the hips, including the buttocks and 
excluding the genitals and anus  
• The arms from the shoulder to the fingertips, excluding  periungual and subungual areas  
• The legs from the hip to the ankles  (including the dorsal side of the foot) . 
 
At Visit 1, each Target  and Non -Target  Wart  must:  
• Have a longest axis that is ≥3mm and  ≤8mm 
• Have a thickness  ≤3mm  
• Be a discrete  lesion  
• Be, when centered in the circular cutout of the provided template, the only 
common wart present (Refer to Figure 2) 
• Not be periun gual, subungual, genital , anal, mosaic, plantar, flat or filiform.  
• Not be covered with hair which, in the Investigator’s opinion, would interfere with 
the study medication treatments or the study evaluations  
• Not be in an area that may be occluded ( e.g., by clothing or footwear or in a  skin fold).  
 
Record the location of the Target  and Non -Target  Wart on the body charts in the CRFs indicating 
landmarks and distances to assist with confirming the location of the Target and Non -Target 
Wart s at subsequent visi ts. 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 33 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
At Visit 1, the Investigator and an investigational staff member will identify each Target and 
Non-Target Wart by placing 2 identification (ID) stickers approximately 180 degrees opposite 
each other with the identified w art in the center of the area outlined by the provided circular 
template (diagram not to scale):  
 
                                                  
                                                                      ID Sticker  
                                                   
 
  
 
                                                                                                           23mm diameter template cutout  
                   Target /Non -Target Wart                                                             
  
 
 
 
 
 
                                                                       
 
              ID Sticker  
Figure 2 Target /Non -Target Wart  Identification  
 
At Visits 2 -13, an investigational staff member (other than the evaluating investigator) will 
confirm the location of each Target /Non -Target  Wart  using an appropriate combination of the 
Visit 1 hard -copy reference prints, Visit 2 photographs and the body charts. The staff member 
will identify the Target /Non -Target  Warts  by placing 2 appropriate ly colored ID stickers, with 
the Target /Non -Target Wart  number written on one sticker, approximately 180 degrees opposite 
each other with the identified wart  in the center of area outlined by the provided circular 
template.  
8.2. Standardized photography  
At Vis its 1, 2 , 4, 9, 10, and 13 a  qualified inve stigational center staff member will take 
standardized color photographs of each Target  and Non -Target  Wart .  
 
The photographs are to document the appearance and location of the subjects’ Target  and Non -
Target  Warts. The subject’s identity will not be revealed in the study photographs.  
 
At Visit 2, the photographs must be taken prior to the study medication application . 
 
Care must be taken to ensure the same lighting, background, subject positioning relative to the  
camera and camera settings are used for each photograph.  
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 34 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Sites will be provided with photography e quipment  and s upplies  necessary for obtaining the 
Target Lesion photographs.  D etailed instructions for obtaining and managin g the photographs 
will be docu mented in the study specific Photography Manual and provided to the site at the 
study initiation visit.    
 
8.3. Physician’s Wart Assessment  (PWA)  
The Physician’s Wart Assessment (PWA) is the Investigator’s assessment of the severity of each 
Target  and Non -Target Wart at a particular time point. The Investigator should NOT refer to any 
other assessments to assist with this evaluation. This evaluation IS NOT a comparison with the 
PWA at any other  visit.  
At every study visit, the Investigator will assess the Targe t and Non -Target  Wart s and report the 
one integer that best describes the Target and Non -Target Wart severity using the following scale. 
At any visit where a study medication treatment is performed, the PWA must be completed 
prior to the treatment.  
 
Physic ian’s  Wart Assessment  
Grade  Descri ptor 
0 Clear: No  visible wart.   No further treatment is indicated  
  
1 Near Clear:  A visible wart that is less than 3mm in maximal diameter (or length)  
2 A visible wart ≥ 3mm and <6 mm in maximal diameter (or length)  
3 A visible wart ≥ 6mm  in maximal diameter (or length)  
At Visit 1 for the subject to be enrolled and at Visit 2 for the subject to be randomized each 
Target  and Non -Target  Wart must have a PWA grade ≥ 2. 
At Visits 3 -9, Target  and Non -Target  Warts must h ave a PWA > 0 to be retreated. If the 
Investigator cannot assess the PWA for a Target or Non -Target Wart ( e.g., the Target /Non -
Target Wart cannot be visualized because of an LSR such as edema, scabbing, etc.) she/he must 
report the reason in the subject’s  CRFs. The Target /Non -Target  Wart must not be retreated at that 
visit, and the subject should be seen at the next scheduled visit. 
8.4. Subject Instructions  
An investigational center staff member will dispense a Subject Instruction Sheet to each subject 
at Visi t 1 (Refer to Appendix 15.1). 
 
Throughout the study, the subjects should:  
• Continue their routine cleansing regimen except they should avoid vigorous scrubbing of 
the Target /Non -Target Warts  (e.g., loofah, back b rushes, scrubbing straps, abrasive 
washcloths, sponges and cleansing pads, etc.)  
• Continue their routine cosmetics and skin care products  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 35 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   • Avoid exposing the Target /Non -Target  Warts  to excessive natural or artificial ultraviolet 
radiation ( e.g., sunlight, ta nning beds) and use sunscreen on the Target /Non -Target  
Warts , if excessive exposure cannot be avoided  
• Avoid activities that might irritate the Target /Non -Target  Wart  
• Avoid the use of self -tanning lotions and spray tans.  
• Bring the subject instruction sheet with them to each visit.  
 
On study visit days, the subjects should:  
• When appropriate for the Target /Non -Target  Wart  location wear loose fitting clothing to 
the visit (Note: clothing that comes in contact with the study medication may be 
bleached)  
• Starting with Visit 2, not apply any topical products to the Target /Non -Target  Wart  
within 12 hours  prior to the visit (Note: routine cleansing products are allowed)  
• After the completion of any study visit where a study medication treatment was 
performed DO NOT:  
o Wash/submerge the Target or Non -Target Warts  for at least 6 hours  
o Apply any topical products to the Target  or Non -Target Warts  for at least 6 
hours . 
8.5. Other Study Supplies  
Aclaris Therapeutics, Inc. will provide:  
• An appropriate ruler, or other instrument, for measuring the thickness of all Target /Non -
Target  Wart s dimensions  
• Templates for use when identifying Target /Non -Target Wart s 
• Supplies and instructions for collecting, labeling, shipping and result reporting for the 
clinical laboratory tests and urine pregn ancy tests from a third party  
• Equipment, supplies and training for taking standardized photographs  
• Scales to weigh all treatment applicators  
• Eyewash kits.  
9. ASSESSMENT OF SAFETY  
In addition to reporting adverse events throughout the study the investigator, a  designated and 
appropriately trained staff member or the subject, will perform the following safety assessments 
according to the schedules noted below.  
 
The investigational staff member performing the LSR evaluations must not participate in the 
study medi cation treatment for the subject being evaluated.  
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 36 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   9.1. Local Skin Reactions (LSR)  
The LSR assessment is the Investigator’s assessment of the signs and the subject’s assessment of 
the symptoms associated with irritation at the Target /Non -Target Wart site ( i.e., the Target /Non -
Target Wart and the skin immediately surrounding the Target /Non -Target  Wart exposed to study 
medication). The Investigator may refer to previous photographs to assist with these assessments  
only after the PWA has been performed.  
The Local S kin Reaction signs to be assessed are:  
• Erythema  
• Edema  
• Erosion  
• Ulceration  
• Vesicles/bullae  
• Excoriations  
• Scabbing.  
 
The Local Skin Reaction symptoms to be assessed (by the Subject) are:  
• Stinging/burning  
• Pruritus (itch).  
 
At Visits 2 -13, the Investigator will evaluate the LSR signs at the Target /Non -Target  Wart 
site(s) as follows:  
• At visits where a study medication treatment or retreatment is  performed:  
o Perform an LSR assessment prior to any study medication  application  
o For treated Target  and Non -Target  Warts p erform an LSR assessment 20 (±4) 
minutes after the Treatment Completion  Time.  
 
At Visits 2 -13, the  Subject will assess the LSR symptoms at the Target/Non -Target Wart site(s) 
as follows:  
• At visits where a study medication treatment or retreatment is  perform ed: 
o Perform an LSR assessment prior to any study medication application  
o For every treated Target  and Non -Target  Wart site, 10 (±4) minutes after the 
Treatment Completion Time, report the average of the severity of the LSR for all 
symptoms since completion of the study medication treatment.  
 
• At visits where no study medication treatment is  performed:  
o Perform an LSR  assessment.  
 
The Investigator and subject should report the one integer that best describes the severity of 
each LSR sign or LSR symptom for the Target and Non -Target Wart site s using the scale 
below.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 37 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
Local Skin Reactions  
Grade  Descriptor  
0 None  
1 Mild  
2 Moderate  
3 Severe  
 
9.2. Vital signs  
Vital signs will be measured by a qualified staff member at Visit 1, Visit 9 and Visit 13 . The 
following ite ms will be measured:  
• Body temperature  
• Pulse rate  
• Respiration rate  
• Blood pressure (systolic and diastolic) after the subject sits quietly for at least 5 minutes  
• Height (at Visit 1 only)  
• Weight (at Visit 1 only).  
 
Any measure that is, in the opinion of the i nvestigator, abnormal AND clinically significant  (CS 
must be recorded as history if found prior to the first study medication treatment or as an AE if 
found after the first study medication treatment begins (Section 10.1).  
 
A systolic blood pressure >140mm Hg or a diastolic blood pressure >90mm Hg is considered 
abnormal and therefore must be defined as CS or not clinically significant  (NCS ) on the CRFs.  
9.3. Clinical laboratory sampling  
Non-fasting blood samples for  clinical laboratory analysis will be collected by a qualified staff 
member at Visit 1 , Visit 9 and Visit 13 . Approximately 7.5 mL of blood will be collected for 
each chemistry sample  and 3 ml of blood will be collected for the complete blood count (CBC) . 
These blood samples will be sent to a central laboratory for analysis.  Refer to the study specific 
laboratory manual for instructions regarding handling of the blood samples and shipping 
instructions.   
The following tests, at a minimum, will be conducted : 
 
Chemistry Panel  Complete Blood Count  
Albumin  Hematocrit  
Alkaline phosphatase  Hemoglobin  
Alanine aminotransferase (ALT)  Platelet count  
Aspartate aminotransferase (AST)  Red blood cell morphology  
Blood urea nitrogen (BUN)  Red blood cell count  
Bicarbo nate White blood cell count  
Calcium  White blood cell differential  
Chloride      % & absolute  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 38 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Creatinine      Basophils  
Glucose      Eosinophils  
Lactate dehydrogenase (LDH)      Lymphocytes  
Phosphorus      Monocytes  
Potassium      Neutrophils  
Sodium   
Total bilirubin   
Total protein   
Uric acid   
 
 
The results of the clinical laboratory tests will be reported on the central laboratory’s standard 
reports. These laboratory results will be sent to the investigator via fax.  The investigator must 
review all la boratory reports in a timely manner and note NC S or C S to define the clinical 
relevance of any result that is outside the normal range for the laboratory. The investigator must 
date and initial every laboratory report.  
 
The investigator must review the Vi sit 1 laboratory results for all the measured analytes for each 
subject prior to Visit 2. The subject must not be randomized at Visit 2 if any of the Visit 1 results 
are outside normal range for the laboratory AND, in the opinion of the investigator, C S. 
 
The investigator must report all laboratory results that are BOTH outside the normal range for 
the laboratory AND, in the opinion of the investigator, C S as medical history if found prior to the 
first study medication treatment or as an AE if found after t he first study medication treatment 
begins.  
 
9.4. Urine pregnancy tests  
The investigator or designee will perform a urine pregnancy test for subjects who are WOCBP at 
Visit 1, at Visit 2 prior to randomization , Visit 9 and Visit 13 .  
 
Subjects who are WOCBP mu st have a negative pregnancy test result at Visit 1 to continue in the 
study and at Visit 2 to be randomized.  
 
If the result of any post -randomization urine pregnancy test is positive, the subject will be 
withdrawn from the study and the subject’s pregnanc y documented and followed  as outlined in 
Section 11. 
 
9.5. Other Evaluations  
9.5.1.  Demographics and medical history  
At Visit 1, the investigator or designee will collect demographic information including date of 
birth, sex  at birth , race and, if appropriate, ethnicity for each subject.  
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 39 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   At Visit 1, the investigator must determine each subject’s Fitzpatrick skin type and document 
appropriately on the subject’s CRF.  
  
Table 3 Fitzpatrick Skin Type Sco ring System  
Skin Type 
Classification  Description  
Type I  always burns, never tans (pale white; blond or red 
hair; blue eyes; freckles)  
Type II  usually burns, tans minimally (white; fair; blond or 
red hair; blue, green, or hazel eyes)  
Type III  sometimes m ild burn, tans uniformly (cream white; 
fair with any hair or eye color)  
Type IV  burns minimally, always tans well (moderate brown)  
Type V  very rarely burns, tans very easily (dark brown)  
Type VI  Never burns, never tans (deeply pigmented dark 
brown to da rkest brown)  
(Fitzpatrick 1988)  
 
Medical history information will be recorded including all medical conditions and disease states 
that, at Visit 1:  
• Are ongoing  
• Require concomitant therapy  
• Are, in the opinion of the investigator, relevant to the subject’s study participation.  
 
9.5.2.  Standardized photography  
At Visits 1, 2 , 4, 9, 10 and 13 , a qualified investigational center staff member, other than the 
investigator, will take standardized color photographs of each Target  and Non -Target  Wart .  
 
The photographs are  to document the location of the Target and Non -Target Wart s and to assist 
with relocating the Target /Non -Target  Wart s.  Th e Target /Non -Target Wart ID stickers must be 
visible in the photographs. The subject’s identity will not be revealed in the study pho tographs.  
 
At Visit 2, the photographs must be taken prior to the study medication treatment.  
Care must be taken to ensure the same lighting, background, and subject positioning relative to 
the camera and camera settings are used for each photograph.  
 
Equipment, supplies, training and detailed instructions for obtaining and managing the 
photographs will be provided to the investigational center prior to the initiation of subject 
enrollment.  
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 40 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   10. ADVERSE EVENTS  
10.1. Definitions  
10.1.1.  Adverse events (AE)  
• An adverse event (AE) is any untoward medical occurrence in a patient that develops 
or worsens in severity during the conduct of a clinical study of a pharmaceutical 
product and does not necessarily have a causal relationship to the study drug.  An 
adverse event can, there fore, be any unfavorable and unintended physical sign, 
symptom, or laboratory parameter that develops or worsens in severity during the 
course of the study, or significant worsening of the disease under study (or any 
concurrent disease), whether or not con sidered related to the study drug.   
Accordingly, an adverse event could include any of the following:  
• intercurrent illnesses  
• physical injuries  
• events possibly related to concomitant medication  
• significant worsening (change in nature, severity, or frequency ) of the disease under 
study or other pre -existing conditions.  (N OTE: A condition, recorded as pre -existing, 
that is intermittently symptomatic [e.g., headache] and which occurs during the study 
should be recorded as an adverse event.)  
• drug interactions  
• events occurring during diagnostic procedures or any washout phase of the study  
• laboratory or diagnostic test abnormalities occurring after the start of the study (i.e., 
after screening and once confirmed by repeat testing) that results in the withdrawal of  
the patient from the study, requires medical treatment or further diagnostic work -up, 
or is considered by the study investigator to be clinically significant.  NOTE: 
Abnormal laboratory test results at the screening visit that preclude a patient from 
entering the study or receiving study treatment are not considered adverse events, but 
will be recorded to monitor data  from patients who do not meet screening criteria.  
Worsening of any of the Target or Non -Target Wart  assessments should be reported as an 
AE ONLY if the use of the study medication is interrupted or discontinued or if therapy is 
required to manage the event.  
 
The investigator must, for any Target  or Non -Target  Wart  related AE, question the subject 
in detail to determine if there are any confou nding factors ( e.g., irritation by clothing or 
activity, sunburn) for any such AE.  
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 41 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   The investigator should, when certain, report a diagnosis rather than the signs, symptoms or 
clinically relevant abnormal laboratory values associated with the AE. Otherwi se, signs, 
symptoms or abnormal laboratory values may be used to describe the AE.  
 
Any C S abnormality discovered prior to the first study medication treatment should be reported 
as medical history, not as an AE.  
 
10.1.2.  Serious adverse event (SAE)  
A Serious Adver se Event is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life threatening  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity,  
• Is a congenital a nomaly/birth defect  or 
• Is an important medical event.  
 
The term “life threatening” refers to an event in which the subject was at risk of death at the time 
of event; it does not refer to an event that hypothetically might have caused death if it was more 
severe.  
 
Inpatient hospitalization is considered to have occurred if the subject is admitted to the hospital 
on an in -patient basis, even if released the same day. Prolongation of hospitalization is defined as 
an additional night stay in the hospital . Hospi talization for elective treatment of a pre -existing 
condition that did not worsen from baseline is not considered an AE.    
 
Important medical events are those that may not be immediately life threatening, result in death 
or hospitalization, but are clearly  of major clinical significance and may jeopardize the subject or 
require intervention to prevent one of the outcomes listed in the SAE definition above. These 
should also usually be considered serious. Examples of such events are intensive treatment in an  
emergency room or at home for allergic bronchospasm, blood dyscrasia or convulsions that do 
not result in hospitalization.  
 
10.1.3.  Adverse event reporting period  
The investigator must start reporting non -serious AEs starting with the subject’s first study 
medica tion tr eatment continuing until Visit 1 1. Non -serious adverse events that occur between 
the time the subject was consent ed and the first application of study medication will be reported 
as medical history.   
 
Reporting for SAEs begins after the subject sig ns the informed con sent and continues until Visit 
11 (regardless of relationship to study medication).  If a subject  experiences a SAE after Visit 11  
that is deemed  by the investigator  to be related to study medication, the investigator must report 
this to  the Sponsor using the study specific SAE report form.    
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 42 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   10.1.4.  Severity  
The investigator must define the severity of each AE using the following definitions as a 
guideline. The investigator will consider the range of the possible severity of the event and 
ident ify the severity that is the most appropriate according to her/his medical judgment.  
 
Mild  – Awareness of signs or symptom, but easily tolerated  
Moderate  – Discomfort, enough to cause interference with usual activity  
Severe  – Incapacitating with inability to perform usual activity.  
 
10.1.5.  Relationship to study medication  
The investigator will determine if there is a reasonable causal relationship between the study 
medication and an AE or not. The investigator will use her/his best medical judgment and 
consider al l relevant factors ( e.g., temporal relationship, location of the event, the subject’s 
relevant medical history, concomitant therapies and concurrent conditions) to determine the 
relationship of the AE to the study medication. The investigator will define t he relationship of an 
AE to the study medication by selecting one of the following categories:  
 
Related  – There is a reasonable possibility that there is a causal relationship between the 
study medication and the AE.  
 
Not Related  – There is not a reasonabl e possibility that there is a causal relationship 
between the study medication and the AE.  
 
The term “reasonable causal relationship” means there are facts or arguments to suggest a causal 
relationship (International Conference on Harmonization (ICH) E2A).  
 
10.2. Reporting Procedures  
10.2.1.  Procedures for reporting adverse events  
At each post enrollment visit, the investigator or designee will question the subject to elicit AEs 
using a non -directive question such as “Has there been any change in your health since the 
previous study visit?”   
 
The Investigator/designee will monitor the subject for at least 20 minutes after the Treatment 
Completion Time at any visit during which a study medication treatment is performed to elicit 
AEs in a similar manner.  
If appropriate, ba sed on the subject’s response to non -directed questioning regarding AEs, the 
investigator or designee will follow -up with directed questions and appropriate evaluations.  
 
Any AE noted during the reporting period must be reported in the source documents an d on the 
appropriate AE CRF.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 43 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
AEs that are defined as “Not Related” to the study medications will be followed until they are 
resolved or until the subject’s last study visit. AEs that are defined as “Related” to the study 
medications will be followed unti l they are resolved or, if not resolved after the subject’s last 
study visit, until in the opinion of the investigator, the AE reaches a clinically stable outcome 
with or without sequelae.  
 
10.2.2.  Procedure for reporting a serious adverse event  
Upon becoming awar e of a SAE occurring during the AE reporting period, whether or not related 
to the study medications, the investigator must:  
 
1. Take the appropriate medical action to ensure the subject’s safety  
2. Immediately inform th e Medical Monitor of the SAE:  
Evyan Cord -Cruz, MD  
Symbio  
Main Number:  631 -403-5126  
Office Number:  516 -338-0647  
Mobile Number:  516 -982-0677  
Serious Adverse Event Facsimile:  484 -324-2359  
Email:  ecruz@symbioresearch.com  
 
3. Within 24 -hours of becoming aware of the event, a SAE report form, an AE CR F and any 
other relevant information ( e.g., concomitant medication CRF, medical history CRF, 
laboratory test results) must be faxed to the SAE Fax line listed above.  
4. Monitor and document the progress of the SAE until it resolves or, if not resolved after t he 
subject’s last study visit, until in the opinion of the investigator the AE reaches a clinically 
stable outcome with or without sequelae AND the investigator and Medical Monitor agree 
that the SAE is satisfactorily resolved.  
5. Inform the Medical Monitor o f SAE updates by telephone followed by an SAE form 
update sent by fax or by e -mail.  
6. Comply with the appropriate regulatory requirements and Aclaris Therapeutics, Inc. 
instructions regarding reporting of the SAE to the responsible Institutional Review Board  
(IRB) or Ethics Committee (EC).  
 
10.2.3.  Withdrawal Due to an Adverse Event  
Any patient who experiences an adverse event may be withdrawn from study drug at any time at 
the discretion of the investigator.  If a patient is withdrawn wholly or in part because of an  
adverse event, both the adverse events page and termination page of the CRF will be completed 
at that time.  The patient will be monitored until the event has resolved or stabilized, until a 
determination of a cause unrelated to the study drug or study pr ocedure is made, or until the 
patient is referred to the care of a local health care professional.  The investigator must inform 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 44 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   the medical monitor as soon as possible of all patients who are being considered for withdrawal 
due to adverse events.  Additio nal reports must be provided when requested . 
11. PREGNANCY  
WOCBP include any female who has experienced menarche and who has not undergone 
successful surgical sterilization ( e.g., hysterectomy, hysteroscopy, bilateral tubal ligation, 
bilateral oophorectomy or bilateral mini -laparo tomy) or is not postmenopausal. Postmenopausal 
is defined as ≥12 months with no menses without an alternative medical cause. Women who are 
WOCBP and are using an active method of birth control, are practicing abstinence or where the 
partner is sterile ( e.g., vasectomy), should be considered to be WOCBP.  
  
All WOCBP must use an active method of birth control during the course of the study, in a 
manner such that risk of failure is minimized.  
 
Prior to trial enrollment, WOCBP must be advised of the importance  of avoiding pregnancy 
during trial participation and the potential risk factors for a pregnancy.  The subject must sign an 
informed consent /assent  form documenting this discussion.  During the trial, all WOCBP will be 
instructed to contact the investigato r immediately if they suspect they might be pregnant ( e.g., 
missed or late menstrual period).  
 
If a subject or investigator suspects that the subject may be pregnant prior to study medication 
administration, the study medication must be withheld until the results of a pregnancy test are 
available.  If pregnancy is confirmed, the subject must not receive study medication and must be 
discharged from the study.  
 
If, following study medication administration, it is determined that the subject may have been or 
was pregnant at the time of study medication exposure (including at least 2 days after study 
medication administration) the investigator must immediately notify the Medical Monitor and 
record the event on a pregnancy surveillance form. While not an AE or S AE, the investigator 
must report every pregnancy using a pregnancy surveillance form and follow the reporting 
procedures described for SAE reporting (Section  10.2.2 ). 
 
Protocol -required procedures for trial discontinuation and follow -up must be performed on the 
subject unless contraindicated by pregnancy ( e.g., x-ray studies). Other appropriate pregnancy 
follow -up procedures should be considered if indicated. In addition, the investigator must report 
to the Medical Monitor on th e pregnancy surveillance form, follow -up information regarding the 
course of the pregnancy, including perinatal and neonatal outcome. Infants should be followed 
for a minimum of six weeks.  
  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 45 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   12. STATISTICAL CONSIDERATIONS  
12.1. Sample Size and Power Considerati on 
Based on efficacy results from the previous study and the active study medication specified in 
the current protocol for the same indication , sample size for the current study is anticipated to 
provide greater than 90% power to achieve statistical significanc e in the primary efficacy 
analysis.  
 
12.2. Statistical Analysis of Efficacy  
 
Primary and secondary efficacy analyses will be performed on the Per -Protocol population, 
defined as all randomized subjects who missed no more than 3 treatment visits, completed Visit  
10 (primary analysis) and Visit 13 (secondary analysis) , and who have not had a major protocol 
violation over that time period, including the use of a clinically relevant quantity of a prohibited 
medication as determined by the study Medical Monitor.  No missing data imputation will be 
used for these analyses.   
 
Visit 10 is considered to be the pri mary efficacy endpoint.  In addition,  some analyses wi ll also 
be conducted at earlier  and subsequent visits , and treated as exploratory analyses.  Some 
sensitiv ity efficacy analyses may also be re -performed on the Intent to Treat population, defined 
as those randomized subjects who have at least one post -baseline visit with required efficacy data 
collection and who completed Visit 10 with required collection of e fficacy data.  For those 
analyses, missing efficacy data for intermediate visits will be imputed using the last observation 
carried forward (LOCF) procedure.   A determination as to the performance of analyses using the 
Intent to Treat population will be ba sed on t he number and pattern of visits  missed  by 
randomized subjects.   Exploratory analy ses using models specified below  may also be performed 
for separate age groups, depending on enrollment outcomes.  
 
For all analyses, two -tail alpha will be set to 0.05  with no adjustment for multiple comparisons.  
ANOVAs and ANCOVAs will include Site in the model only if doing so improves the 
sensitivity of the model for comparing treatment groups.  
 
After the last randomized subject has completed Visit 10 the database w ill be validated, locked 
through Visit 10 and unbli nded for the purpose of analyzing  efficacy data through Visit 10.  
Those analyses are not considered to be interim analyses as the results will be final.  Data will 
continue to be collected through Visit 1 3 for all subjects,  and the full database will subsequently  
be locked for efficacy analysis ( including durabili ty of response) beyond Visit 10, and for the 
analysis of safety  and all other clinical  data. 
 
The primary efficacy analysis will be a comparison between treatment groups based on the mean 
change in Target Wart PWA from Baseline (Visit 2) to Visit 10, using Analysis of Covariance 
with Baseline PWA as the covariate.   
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 46 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   Secondary efficacy analyses will include comparisons between treatment groups base d on the 
following:  the proportion of subjects with the Target Wart Clear (PWA = 0) at Visit 10 using 
Fisher’s Exact Test; the proportion of subjects with all treated warts Clear at Visit 10 using a 
Cochran -Mantel -Haenszel test stratified by number of tre ated warts; and the mean of per -subject 
percentages  of treated warts that are clear at Visit 10 using Analysis of Variance.  The number of 
treated warts Clear at Visit 10 will also be analyzed using a Cochran -Mantel -Haenszel test 
stratified by number of tre ated warts.    
 
Durability of response in the Active treatment group will be evaluated by calculating the 
proportion of tho se treated warts achieving a PWA  status of Clear at Visit 10 which continue to 
maintain a PWA  status of Clear at Visit 13.  This analy sis will be performed separately for 
Target Warts, and for all treated warts.  The 95% confidence limits around the calculated 
proportions will also be calculated in order to estimate the population lower limit value of the 
observed sample proportions.  
 
Exploratory analyses will be conducted using a subset of the above analysis models, based on the 
following baseline wart classifications:   warts that are determined to be tr eatment -naive vs. 
recalcitrant.  
 
12.3. Statistical Analysis of Safety Data  
Descriptive sta tistics will be calculated on the safety parameters using the ITT population. The 
proportion of subjects with treatment -emergent adverse events will be tabulated and presented by 
treatment and Medical Dictionary for Regulatory Activities (MedDRA) System Or gan Class. 
Vital signs, LSR scores and clinically relevant abnormal laboratory results will also be tabulated 
and presented by study medication. No inferential testing will be performed.  
 
Data from all randomized subjects will be presented and summarized. Safety summaries by study 
medication group will include listings by study medication of  adverse events incidences within 
each MedDRA System Organ Class, and changes from  pre-application values in vital signs. 
Adverse event summaries will be presented by  study medication showing the proportion of 
subjects experiencing adverse events, both  overall and by MedDRA System Organ Class.  
12.4. Interim Analysis  
An interim Analysis will not be conducted for this study.     
 
13. QUALITY CONTROL AND QUALITY ASSURANCE  
13.1. Protocol Ame ndments  
No changes from the final approved (signed) protocol will be initiated without the prior written 
approval or favorable opinion of a written amendment by the IEC/IRB, except when necessary to 
eliminate immediate safety concerns to the  study subjects  or when the change involves only 
logistics or administration.  The principal investigator and the sponsor will sign the protocol 
amendment . 
 
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 47 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   13.2. Protocol Deviations, Violations and Exceptions  
A protocol deviation  is non -adherence to protocol -specific study pr ocedures or schedules that 
does not involve inclusion/exclusion criteria, primary objective variable criteria, and/or GCP  
 guidelines.  Deviations are considered minor and do not impact the study.   Deviations include 
study procedures that occurred outside the treatment windows (except for treatment application 
days) .  
 
A protocol violation  is defined as any divergence from the protocol -specific inclusion/exclusion 
criteria, subject is administered a p rohibited medication , primary objective variable criteria , 
and/or GCP guidelines .  Protocol violations will be identified and recorded, by study center 
personnel, on the CRF.  
 
As a matter of policy, sponsor/CRO will not grant exceptions  to protocol -specific entry criteria 
to allow patients to enter a study.  If under extraordinary circumstances such action is considered 
ethically, medically, and scientifically justified for a particular patient, prior approval from 
sponsor/CRO and the responsible IRB/IEC, in accordance with the Sponsor/CROs Standard 
Operating Pro cedure (SOP), is required before the patient will be allowed to enter the study.  If 
investigative center personnel learn that a patient who did not meet protocol eligibility criteria 
was entered in a study (a protocol violation), they must immediately inf orm sponsor/CRO.  Such 
subjects  will be discontinued from the study,  except in a rare instance following review and 
written approval by sponsor/CRO and the responsible IRB/IEC, according to the applicable SOP . 
13.3. Training  
For each investigational center, ther e will be an initiation visit prior to enrolling any study 
subjects.  
 
It is strongly recommended that all investigators, other evaluators, study nurses, study 
coordinators or other applicable personnel attend this visit.  During this visit, participants wi ll be 
trained to the protocol, study specific procedures, and the CRFs.  Those unable to attend the 
initiation visit must receive on -site training from an appropriately trained individual prior to 
participating in any of the procedures and evaluations in t his study.  
 
Clinical Research Associates (CRAs) and other applicable personnel will be trained prior to 
study initiation to familiarize CRAs with the disease, the Standard Operating Procedures (SOPs), 
the protocol and other study specific items.  Team org anization, communication and operational 
issues will also be discussed.  
 
Aclaris Therapeutics, Inc. will provide an investigational center file to each center.  
 
13.4. Monitoring  
The conduct of the study will be closely monitored by the Aclaris Therapeutics, Inc.  study 
monitor /CRO to verify adherence to ICH Good Clinical Practice (GCP) guidelines, applicable 
SOPs, the protocol, other written instructions and regulatory guidelines.   
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 48 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   The investigator will allow the Aclaris Therapeutics, Inc. representatives design ee and/or and 
any regulatory agency to have direct access to all study records, CRFs, corresponding subject 
medical records, study medication dispensing records and study medication storage area, and any 
other documents considered source documentation.  Th e investigator also agrees to assist the 
representative, if required .  
13.5. Data Management  
Data will be collected using eCRFs that are specifically designed for this study.  The data 
collected on the eCRFs will be captured in a clinical data management system (CDMS) that 
meets the technical requirements described in US 21 Code of Federal Regulations (CFR) Part 11.  
The CDMS will be fully validated to ensure that it meets the scientific, regulatory, and logistical 
requirements of the study before it is used to c apture data from this study.  Before using the 
CDMS, all users will receive training on the system and study specific training.  After they are 
trained, users will be provided with individual system access rights.  
The handling of data, including data quali ty assurance, will comply with regulatory guidelines, 
including ICH and GCP, and the sponsor/CRO SOPs and working instructions.  Data 
management and control processes specific to this study will be described in a data management 
plan.    At the end of the study, the database will be locked and the data will be released for  
reporting and statistical analysis  
13.6. Quality Assurance  
The study is conducted under the sponsorship of Aclaris Therapeutics, Inc. in compliance with 
the applicable regulatory requirements a s well as applicable ICH guidelines, Helsinki 
Declaration, and in respect of the Aclaris Therapeutics, Inc. and/or sub -contractor SOPs for study 
conduct and monitoring.  
Audits may be carried out by the Aclaris Therapeutics, Inc. or Aclaris Therapeutics, In c.’s 
representatives and inspections may be performed by regulatory authorities or IRB/ECs before, 
during or after the study.  The investigator will provide the auditing/inspecting group direct 
access to all study records ( e.g., CRFs, subject medical recor ds, study medication dispensing 
records) and the investigational center study facilities. The investigator and study staff will be 
available and will assist the auditing/inspecting groups as appropriate.  
13.7. Record Retention  
All pertinent data, samples, photo graphs, correspondence, original or amended protocol, reports 
and all other material relating to the study will be maintained securely in Aclaris Therapeutics, 
Inc./CRO /investigator archives for the legally required duration for archiving.  
The investigator  should maintain the essential study documents as specified in ICH GCP, and in 
compliance with all regulatory requirements. The investigator should ensure these documents are 
protected from accidental destruction or disposal.  
If the Investigator needs to r e-assign responsibility for maintaining these documents ( e.g., due to 
retirement) it must be transferred to a person willing to accept this responsibility.  The 
investigator must notify Aclaris Therapeutics, Inc., in writing, of the name and address of the  
new individual.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 49 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                   If the Investigator cannot guarantee this archiving requirement at the investigative site for any or 
all of the documents, special arrangements must be made between the Investigator and the 
Sponsor to store these in sealed containers in an  off-site storage location so that they can be 
returned to the Investigator in case of a regulatory audit.  Where source documents are required 
for the continued care of the patient, appropriate copies will be made for off -site storage.  
No trial document s hould be destroyed without prior written agreement between the Sponsor and 
the Investigator. Should the Investigator wish to assign the trial records to another party or move 
them to another location, the Investigator must notify the Sponsor in writing of the new 
responsible person and/or the new location  
14. ETHICS AND GENERAL STUDY CONDUCT CONSIDERATIONS  
14.1. Institutional Review Board (IRB) /Ethics Committee (EC)  
This protocol and any accompanying material, including information that will be provided to 
prospectiv e patients (such as advertisements, patient information sheets, or study descriptions 
used to induce study participation or obtain informed consent /assent ) must be submitted to the 
Central  IRB for approval .  Approval of each such submission must be obtaine d from the 
committee before it may be used in the study and must be documented in a written notification to 
the Investigator specifying the protocol number, protocol version, documents reviewed, and date 
on which the committee met and granted the approval.   In particular, each informed 
consent /assent  document must bear clear evidence (written, stamp, date of approval, etc.) of IRB 
approval before it may be presented to prospective (or ongoing, as appropriate) study patients for 
signature.  
Written evidence o f the approval must be made available to the Sponsor.  Any modifications 
made to the protocol and of correspondingly modified informed consent /assent  documents made 
after receipt of Central IRB approval must also be submitted to the committee for approval 
before implementation unless the modification is made on an emergency basis to protect the 
welfare of study patients.  In the latter case, the Central IRB must be notified promptly and their 
written approval must be obtained as soon after the fact as possi ble. 
Appropriate reports on the progress of the study will be made to the Central IRB and the Sponsor 
by the Investigator in accordance with applicable regulatory regulations and in conformity with 
policies established by both the  Central  IRB and the Spons or.  The shortest time interval between 
required reports required by either party or by regulations will prevail.  
The Investigator at each investigative site, or his/her nominee, will be responsible for reporting 
any SAEs to the Central IRB as soon as poss ible, and in accordance with the guidelines of the 
Central IRB.  
The Sponsor will be responsible for reporting all serious, life threatening or fatal adverse study 
drug events with a causal relationship to the study drug to appropriate regulatory agencies w ithin 
their required timelines.  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 50 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    The Investigator is responsible for obtaining written, informed consent /assent (s) from each 
prospective patient interested in participating in this study before performing any study -related 
procedures.  Written informed con sent must be obtained after adequate, thorough, and clear 
explanation of the aims, methods, objectives, and potential hazards of the study, as well as any 
use of the patient’s genetic information from the study.  The Investigator must use the most 
current Central IRB-approved consent form for documenting written informed consent.  Each 
informed consent will be appropriately signed and dated by the patient and the person obtaining 
consent and each page not signed must be initialed and dated by the patient.  The investigational 
site must retain the original signed consent and provide a copy to the patient.   
14.2. Ethical Conduct of the Study  
The Sponsor will use information developed in this clinical study in connection with the 
development of A -101 Solution and, t herefore, may disclose it as required to other clinical 
Investigators participating in other studies and to regulatory agencies.  In order to allow the use 
of the information derived from this clinical study, the Investigator understands that he/she has 
an obligation to provide all data produced during this study to the Sponsor.  
The Sponsor considers that clinical data (complete or incomplete) constitute financially sensitive 
information.  Consequently, the Sponsor requires that discussion of results in any  form, 
electronic, verbal, or written before study completion and full reporting should only be 
undertaken with the Sponsor’s prior written consent.  
Individual patients’ medical information obtained as a result of this study is considered 
confidential.  Th e Investigator and the study center will adhere to all applicable laws relating to 
the protection of patient information.  To assure that patients’ confidentiality is maintained, 
patients’ data will be identified by a study -assigned number .  
All Sponsor pe rsonnel will handle patients’ data in a confidential manner in accordance with 
applicable regulations governing clinical research.  Subject s’ records will be inspected only in 
connection with this research project.  Information generated as a result of a subject ’s 
participation in this study may be disclosed to third parties for research and regulatory purposes 
in any country as determined by the Sponsor.  However, subject s will not be individually 
identified but will be referred to only by the study assign ed number . 
14.3. Regulatory Documents  
The investigator must maintain a study file containing current and complete regulatory 
documentation in compliance with the current ICH E6 GCP guideline. This file will be reviewed 
as part of the routine monitoring for this study.  
 
14.4. Contractual Requirements  
A contractual agreement will be signed between Aclaris Therapeutics, Inc. and each investigator.  
This document will contain supplemental information, including financial terms, confidentiality, 
study schedule, third party responsibility, and publication rights.  
 
 
  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 51 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
15. APPENDICES  
15.1. Subject Instruction Sheet  
A-101-WART -202 SUBJECT INSTRUCTION SHEET  
Please follow these instructions carefully. Contact the study staff at the telephone number noted 
below if you have any questions ab out the study:  
Contact:          Telephone:                                        
THROUGHOUT THE STUDY:  
• Continue your routine cleansing regimen except avoid vigorous scrubbing of the Target 
and Non -Target Warts (e.g., abrasive cleansing pads, abrasive clean sers, etc.)  
• Continue your routine skin care products  
• Avoid exposing the Target  and Non -Target  Warts to excessive natural or artificial 
ultraviolet radiation ( e.g., sunlight, tanning beds) and use sunscreen on the warts, if 
excessive exposure cannot be avoi ded 
• Avoid activities that might irritate the  Target  or Non -Target  Warts 
• Bring this subject instruction sheet with you to each visit.  
 
STARTING WITH VISIT 2:  
• On visit days, do not apply any topical products ( e.g., moisturizers, sunscreens) to the 
Target and Non-Target Warts , except for routine cleansing products, within 12 hours 
prior to the visit  
• After any study visit where a study medication treatment occurred do not:  
o Wash/submerge the warts for at least 6 hours after the treatment  
o Apply any topical products to the wart for at least 6 hours  
o Occlude, bandage or otherwise cover the wart treatment area (loose -fitting clothing is 
permissible) for at least 6 hours.  
STUDY VISIT SCHEDULE : 
VISIT 2:  
Date:                            Time:  VISIT 3: 
Date:                            Time:  
VISIT 4:  
Date:                            Time:  VISIT 5:  
Date:                            Time:  
VISIT 6:  
Date:                            Time:  VISIT 7:  
Date:                            Time:  
VISIT 8:  
Date:                            Time:  VISIT 9:  
Date:                            Time:  
VISIT 10:  
Date:                            Time:  VISIT 11:  
Date:                            Time:  
VISIT 12:  
Date:                            Time:  VISIT 13:  
Date:                            Time:  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 52 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
THANK YOU FOR FOLLOWING THESE INSTRUCTIONS  
Protocol: A -101-WART -202 Aclaris Therapeutics, Inc.  
 
 
Page 53 of 53 
Amendment 2 
Version 3    
Date:   05 December  2017                                                                                                    
16. References  
Chan HP, Maibach HI,. 2008. "Hydrogen Peroxide, Blanching, and Skin: an Overview." 
Cutaneous and Ocular Toxicology  307-309. 
Fitzpatrick, TB. 1988. "The Validity and Practicality  of Sun Reactive Skin Types I through VI." 
Arch Dermatology  869-871. 
Haffner C, Vogt T. 2008. "Seborrheic keratosis." JDDG: Journal der Deutschen 
Dermatologischen Gesellschaft  6(8):664 -677. 
McKee PH, Calonje E, Granter S. 2005. "Seborrheic Keratosis." In Pathology of the Skin with 
Clinical Corrections , by Calonje E, Granter S McKee PH, Vol 2: 1158 -1163. 
Philadelphia: Mosby.  
Motley. 2002. "Seborrheic Keratosis." In Treatment of Skin Disease Comprehensive Therapeutic 
Strategies , by Heymann W, Berth -Jones J, C oulson I Lebwohl M, 585 -586. New York: 
Mosby.  
Pierson DBC, Bandel C, Ehrig T, Cockerell C. 2003. "Benign Epidermal Tumors and 
Proliferations." In Dermatology , by J, Jorizzo J, Rapini, R Bolognia, Vol 2 1 ed. 1697 -
1703. NY: Mosby.  
Richardson. 1891. "On Pero xide of Hydrogen, or Ozone, or Water as a Remedy: Continued from 
a Research Commenced in the Year 1858." The Lancet  137(3527):760 -763. 
Richardson. 1891. "On Peroxide of Hydrogen, or Ozone, or Water, as a Remedy: Continued 
from Research Commenced in the Yea r 1858." The Lancet  137(3526):707 -709. 
Richardson. 1866. "On the Introduction of Peroxide of Hydrogen as a Medicine." The Lancet  87 
(2220):300.  
Schumb WC, Satterfield CN, and Wentworth RL. 1955. Hydrogen Peroxide.  New York: 
Reinhold Publishing Comp.  
Watt B E, Proudfoot AT, Vale JA. 2004 . "Hydrogen Peroxide Poisoning (Review)." 
Toxicological Reviews  51-57. 
Zonios. 2007. "Probing Skin Interactionwith Hydrogen Peroxide Using Diffuse Reflectance 
Spectroscopy." Physicis in Medicine and Biology  269-278. 
 
 
 
 
 
 
 